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Recently, the increase in the number of newly discovered poorly water-soluble drug 
candidates has heightened the interest in developing novel methods to improve 
solubility of active pharmaceutical ingredients (APIs). Amorphization is an emerging 
technique to enhance the dissolution of poorly water-soluble drug. In amorphous form 
the ordered crystalline lattice is not presence, thus providing the maximal solubility 
advantages as compared to the crystalline and hydrated forms of a drug. There are 
several strategies to generate amorphous drug substances such as solvent evaporation, 
co-milling (COM), melt-extrusion, spray-drying, melt-quenching and supercritical 
fluids technology. In this thesis, the effectiveness of a low-cost and easily scalable 
process COM was compared with the high-cost and precise-controlled supercritical 
anti-solvent (SAS) process to amorphize indomethacin (IDMC) with a water-soluble 
polymer excipient poly(vinylpyrrolidone) (PVP) to improve the aqueous-solubility as 
well as physical stability of IDMC amorphous form.  
 
Both COM and SAS co-precipitation were conducted at IDMC to PVP ratios of 60:40, 
50:50 and 20:80. The untreated, COM and SAS powders were characterized using 
scanning electron microscopy (SEM, morphology), X-ray powder diffractometry 
(XRD, crystallinity), thermogravimetric analysis (TGA, composition), differential 
scanning calorimetry (DSC, glass transition temperature (Tg)), USP dissolution tester, 
gravimetric vapour sorption (GVS, moisture isotherms), Fourier-transform infrared 
spectroscopy (FTIR, drug-polymer interactions), inverse gas chromatography (IGC, 
surface energetic and structural relaxations) and Raman mapping (RM, spatial 
distribution). The residual solvent content in SAS processed samples were evaluated 
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using gas chromatography (GC). Accelerated stability stress tests were also conducted 
on COM and SAS co-precipitates in open pans at 75%RH/40oC. 
 
Amorphous forms of IDMC produced by COM and SAS have significantly improved 
the dissolution rate of IDMC as compared to the crystalline form and its physical 
blends, respectively. SAS IDMC-PVP co-precipitates with PVP contents at more than 
40wt.% were X-ray amorphous form and remained stable after more than 6 months of 
storage at 75%RH/40oC. COM IDMC-PVP samples with PVP contents less than 
50wt.%  re-crystallized after 7 days of storage at 75%RH/40oC. FTIR also revealed 
there were interactions between IDMC and PVP in both COM and SAS co-precipitates 
and PVP may influence the re-crystallization kinetics by preventing the self association 
of indomethacin molecules. IGC studies also revealed that the two different 
preparation methods have an effect on its physical stability in terms of surface 
structural relaxation as well as having different surface energetics. Overall the surface 
structural relaxation of SAS co-precipitate was slower than COM samples indicating 
that SAS co-precipitate was physically more stable than COM sample. Raman 
mapping results showed the presence of crystalline γ-IDMC phase in COM sample, 
which may has acted as the precursor for the re-crystallization of COM sample. The 
Raman spatial distribution mapping suggested that co-linearity in composition between 
PVP and amorphous IDMC in SAS sample, which resulted in the reconstruction of 
single component spectrum that are resemblance to Raman peaks of PVP and 
amorphous IDMC pure component references. 
 
It was demonstrated that the drug to polymer ratio influenced the amorphous content of 
the SAS co-precipitates. By using different polymer ratios, the morphologies of a drug-
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polymer composite can be varied using SAS process but not for co-milling.  The 
values of Tg as a function of mixture composition were comparable to the ideal 
Gordon-Taylor equation for both COM and SAS co-precipitates. TGA analyses 
revealed that the composition of both COM and SAS co-precipitates were consistent 
with the experimentally designed compositions. GC analysis shows that residual 
solvents content in all the SAS processed samples were way below the acceptable 
maximum limit based on the International Conference of Harmonization (ICH) 
guidelines.  
 
This work has demonstrated the potential of using a suitable “amorphous inducing and 
stabilizing” agent as a co-precipitant for a poorly water-soluble drug such as IDMC to 
improve the bioavailability using SAS process. The co-precipitant used in this work 
such as PVP to generate amorphous IDMC-PVP co-precipitates using co-milling and 
SAS process showed improved physical stability (through hydrogen bonding 
formation between IDMC and PVP) as compared to the IDMC amorphous form. 
Furthermore, this study could provide a practical reference in helping to evaluate other 
co-precipitants. The amorphous forms of SAS IDMC-PVP co-precipitates have 
increased the dissolution efficiency of IDMC at 5 minutes (DE5%) to about 9-times as 
compared to its crystalline form The use of KWW equation in IGC analysis may has 
provided some useful insights on the amorphous surface structural relaxation prepared 
using COM and SAS processes, which could be related to a faster re-crystallization at 
the surface due to higher surface molecular mobility as compared to the bulk. Finally, 
this study could also provide a practical reference in tackling frequently reported 
physical stability issues during the development of pharmaceutical drug delivery 
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1.1 Research Background 
In pharmaceutical industry, solid oral dosage forms of crystalline active 
pharmaceutical ingredient (API) are normally the most preferred state. Moreover, 
about two thirds of the drug products used in the pharmaceutical industry are in the 
form of particulate solids [1]. Consequently, a lot of efforts have been put into research 
in particle generation processes to produce particles of desired size, morphology and 
crystalline structures. Besides that, APIs may exist in different solid-state and the 
polymorphism of crystalline API is one of the main focuses in pharmaceutical 
research. In crystalline polymorphs, API molecules can have different arrangements 
and conformations in the crystal lattice, and thus having long-range molecular order. 
The most thermodynamically stable polymorph is commonly used to develop the final 
drug product and is unlikely to transform to different polymorphs during processing, 
transportation and storage. However, with recent advances in molecular screening 
techniques for identifying potential drug candidates, an increasing number of newly 
discovered poorly water-soluble drug candidates pose challenges for drug development 
and delivery. It has been estimated that approximately 40% of new chemical entities 
have little or no water solubility [2]. Therefore, it has heightened the interest in 
developing new patents and novel techniques to improve/enhance aqueous-solubility. 
There are numerous formulation strategies and techniques to enhance aqueous-
solubility of poorly water-soluble drugs such as pro-drugs, salt formation, 
micronization, preparation of solid dispersions with water-soluble polymer or 
converting the crystalline drug to the amorphous form [3-5].  
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Currently, the use of amorphous forms of APIs in various solid formulations has 
received considerable attention to enhance/improve aqueous solubility. The amorphous 
form of API is desirable mainly due to the advantageous of solubility, dissolution rate 
and compression characteristics that it offers over crystalline forms [6, 7]. Hancock 
and Parks [8] reported that the experimental solubilities of amorphous solids are at 
least 2–4 times greater than their crystalline counterparts. There are two feasible ways 
to amorphize crystalline APIs. First, an amorphous API can be generated alone, 
without additives. However, the generated amorphous solids are mostly 
thermodynamically unstable as compared to its crystals due to the higher energy level 
[9-11] and have the tendency to revert back to its crystalline form especially during 
storage at different temperatures and relative humidities [12]. The other method is to 
generate amorphous solid dispersions to attain good physical stability as well as 
enhanced dissolution and bioavailability. This technique utilizes crystallization 
inhibitors such as additives together with the APIs [13-16] to generate a single-phase 
amorphous mixture. These additives/inhibitors are usually hydrophilic carriers 
(polymers or sugars) and could inhibit re-crystallization and generate a more stable 
amorphous solid form as well as to increase the wetting property of APIs. As a result, 
the dissolution rate of a poorly water-soluble drug can be improved by dispersing it in 
a water-soluble biocompatible carrier such as poly(vinylpyrrolidone) (PVP), 
polyethylene glycol, hydroxylpropylmethylcellulose, etc., which could inhibit the re-
crystallization of the drug. This approach leads to composite particle formation such as 
those obtained from solid solution and dispersion technologies for drug substances. 
The effect of a polymer on the re-crystallization rate of amorphous substances is 
generally expressed in terms of properties of the meta-stable amorphous form such as 
the molecular mobility, the glass transition temperature (Tg) and the interactions 
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arising between the drug and the polymer. Substances with higher entropy and 
enthalpy than the steady crystalline form, such as the amorphous or polymorphic forms 
can be obtained using these technologies by modifying the molecular structure of the 
crystals. The amorphous state of the drug can be stabilized by dissolving the drug into 
the polymer matrix at molecular level and restricting the mobility of the drug 
molecules, thus hindering the re-crystallization process. There are a number of 
different methods to generate the amorphous form of APIs and/or amorphous solid 
dispersions such as solvent evaporation [17], co-milling (COM) [18, 19], melt-
extrusion [20, 21], spray-drying [22], melt-quenching [23] and supercritical fluids 
(SCF) technology [24-27]. However, some of these applications may be difficult due 
to the thermal and decomposition instability of drug during melting, which often poses 
a major problem [8-9].   
 
Among the various methods that can generate amorphous form, milling is a common 
unit operation employed for particle size reduction which is relatively low-cost and an 
easily scalable [28, 29] manufacturing process. Depending on the crystal structure, 
milling can either yield highly strained crystals with small particle size or the crystals 
can lose their crystalline structure completely and form the amorphous state as in 
indomethacin [30], piroxicam [31], budesonide [32] and sucrose [33]. However, this 
process may also cause several undesirable effects on APIs such as aggregation of fine 
particles, induction of electrostatic charges, mechanochemical transformation, APIs 
degradation and solid-state reactivity [34-37], and leading to limitation in the use of 
the milling process itself. In order to improve the milling efficiency, a favourable 
method using co-milling (COM) of drug with additives/polymers has been successfully 
applied [19, 36, 38]. Various amorphous solid dispersions were generated by co-
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milling of PVP with ibuprofen, sulfathiazole, phenothiazone, acridine, chloranil and 
vitamin K3 [39-41]. Bahl et al [19] investigated the amorphization of indomethacin 
(IDMC) using co-milling with six pharmaceutical silicates and the co-milled 
amorphous indomethacin was physically stable for 3 to 6 months at 40oC/75%RH. 
 
Recently, the use of SCF technologies in pharmaceutical applications has received 
considerable attention. Some of these SCF technologies are supercritical fluid 
extraction (extraction of seed nutrient component for use in pharmaceutics) [42], 
chemical reaction (oxygenation, hydro-formulation and alkylation) [43], supercritical 
fluid chromatography (analytical technique for the separation and analysis of drug 
molecules) [42], supercritical fluid fractionation (phyto-pharmaceuticals preparation) 
[44], polymer processing [42, 45, 46], particle coating or encapsulation [27, 46, 47] 
and particle formation/design [27, 45]. The new approach of using SCF technologies 
for particle design of pharmaceutical materials is one of the most actively pursued 
applications due to its major advantages over conventional pharmaceutical processing 
such as high purity of products, ability to control particle size and narrow particle size 
distribution, able to process thermo-labile materials, single-step process and generally 
free from residual solvent [27, 48, 49]. Besides that, carbon dioxide is commonly used 
as the SCF for pharmaceutical materials processing due to its relatively mild critical 
pressure and temperature, non-toxic, relatively inert, non-flammable, and recyclable. 
There are several SCF particle formation techniques available such as rapid expansion 
of supercritical solution (RESS), gas anti-solvent (GAS), supercritical anti-solvent 
solution (SAS), solution enhanced dispersion by supercritical fluids (SEDS) and 
particles from gas-saturated solutions (or Suspensions) (PGSS) to form particles using 
Sc-CO2.  A more detail description of each of the SCF particle formation techniques is 
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given in Chapter 2.5. The early studies using SCF particle formation technologies were 
focused on particle size, particle size distribution, particle morphology, polymer 
processing and polymer coating or encapsulation [26, 27, 45, 46]. Most of the works 
reported in literature are related to particle generation and formulation techniques in 
order to enhance the dissolution rate by micro or nanosization through increased of 
particle surface area [24, 26, 27, 49, 50]. The influence of the crystalline structure 
(surface chemistry, polymorphism, amorphous phase) has previously attracted less 
attention. 
 
Recently, research in the amorphization of pharmaceutical compounds by co-
precipitation (solid dispersion formation) using supercritical fluids processing has 
attracted much attention [51-54]. Kluge et al. [52] studied the effect of phenytoin to 
PVP ratios using precipitation with compressed anti-solvent (PCA) process and 
obtained X-ray amorphous co-formulations at PVP contents of 60wt.% and above. 
Besides that, these amorphous co-formulations remained stable after one year of 
storage at ambient conditions. Sethia and Squillante [55] generated carbamazepine 
solid dispersion in PVP prepared using conventional solvent evaporation and a 
supercritical carbon dioxide (Sc-CO2) process. It was reported that the intrinsic 
dissolution of carbamazepine solid dispersion in PVP generated by Sc-CO2 process 
was 4-fold higher as compared to its crystalline form. Gong et al. [56] successfully co-
formulated of IDMC and PVP particles using solvent-free supercritical fluid technique. 
The X-ray amorphous products were obtained at relatively high PVP weight fractions 
of 0.8 and above. Mauro et al. [57] successfully impregnated piroxicam and PVP using 
supercritical solvent impregnation process and X-ray amorphous impregnated samples 
were obtained at PVP contents of 85wt.% and above. They also reported that polymer 
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molecular weight was mainly found to affect the dissolution rate of the different 
formulations. Thus, the drug to polymer ratio plays a crucial role in the generation of 
co-formulation. A critical ratio between drug and excipient in the final co-formulation 
should be attained to ensure sufficient shelf life and drug therapeutic efficacy. 
However, this optimisation requires more understanding on the drug-polymer 
thermodynamic system and the nature of amorphous character, which has not been 
well reported.  
 
It has been shown that the choice of processes used to prepare the amorphous form has 
an influence on its physical stability in terms of enthalpic relaxation and crystallization 
behaviour [58]. In addition, structural relaxation of amorphous materials is believed to 
be the precursor to re-crystallization. Bhugra et al. [59, 60] reported that there is a 
relationship between the structural relaxation and the onset time of the re-
crystallization. Amorphous materials undergo structural relaxation to dissipate excess 
energy during aging/storage because of its higher energy state as compared to the 
equilibrium state [61, 62]. Moreover, it is often known that re-crystallization started to 
occur at the surface of amorphous materials. Crowly and Zografi [63] reported that 
smaller particles of amorphous IDMC and IDMC-PVP solid dispersion re-crystallized 
faster as compared to the larger particles, indicating surface-mediated nucleated 
occurred. Recently, Hasegawa et al. [64] investigated the structural relaxation of 
amorphous IDMC-PVP solid dispersion using inverse gas chromatography (IGC) and 
concluded that structural relaxation at the surface occurred faster as compared to the 
bulk. Ke et al. [65] investigated the effect of preparation methods on surface structural 
relaxation using IGC and reported that the surface has higher molecular mobility than 
the bulk in all systems prepared. Hence, it will be advantageous and useful to 
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investigate the surface structural relaxation of amorphous materials to 
predict/understand its tendency to re-crystallize which is important for formulation 
design and product manufacturing.  
 
1.2 Research Objectives 
The main objective of this study is to employ supercritical anti-solvent (SAS) co-
precipitation process as a potential new ways to amorphize pharmaceutical compound 
using water-soluble polymer to generate a physically stable amorphous solid 
dispersion with enhance/improve the dissolution properties. Besides that, the 
effectiveness of a low-cost and easily scalable process co-milling (COM) is compared 
with the high-cost and precise-controlled supercritical anti-solvent (SAS) co-
precipitation process. The model drugs used in our study is indomethacin (IDMC, a 
poorly water-soluble API) and the water-soluble polymer excipient is 
poly(vinylpyrrolidone) (PVP). 
 
The specific objectives of this study are:  
I. To investigate the feasibility of using SAS process to influence the crystallinity 
or amorphous character of crystalline IDMC for dissolution properties 
enhancement, 
 
II. To study the effect of IDMC to PVP ratios on amorphization of COM and SAS 
co-precipitated powder and its physical stability under accelerated storage 
condition (75%RH/40oC), 
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III. To study and understand the nature of amorphous IDMC in PVP generated by 
COM and SAS co-precipitation process using Raman microscopy and FTIR, 
 
IV. To study the surface energetic properties of amorphous solid generated by 
COM and SAS processes using IGC and 
 
V. To investigate the surface structural relaxation of amorphous COM and SAS 
co-precipitated powder using IGC. 
 
1.3 Organization of Thesis 
This thesis is organized into five chapters. Chapter 1 provides an introduction and 
research background of solid dosage formulation for drug delivery systems, especially 
on improving the dissolution rate of poorly water-soluble drug. The objective of our 
research work is defined. 
 
Chapter 2 outlines the current challenges in drug development and delivery systems. It 
also includes recent approaches and formulation strategies to enhance the dissolution 
rate of poorly water-soluble drug. Among all techniques discussed, co-milling and 
supercritical fluid technologies for particle formation and solid dispersion were 
selected and a more detailed review on recent research was discussed. Besides that, the 
recent analytical methods used to characterize solid dispersions were also covered in 
this chapter. 
 
Chapter 3 describes the material and experimental procedures used in this study. The 
COM and SAS experimental set-ups employed to generate solid amorphous forms 
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were outlined. It also includes characterization procedures such as powder X-ray 
diffractometry (XRD, crystallinity), scanning electron microscopy (SEM, 
morphology), differential scanning calorimetry (DSC, glass transition temperature), 
USP dissolution tester, accelerated physical stability evaluation, gravimetric vapour 
sorption (GVS, moisture sorption isotherm), Fourier-transform infrared spectroscopy 
(FTIR, drug-polymer interactions), inverse gas chromatography (IGC, surface 
energetic and structural relaxations), Raman mapping (RM, spatial distribution), 
thermogravimetric (TGA, composition) and gas chromatography (GC, residual 
solvent), used in this study. 
 
In Chapter 4, experimental results are summarized and discussed. The accelerated 
physical stabilities of COM and SAS co-precipitates were compared and discussed. In 
addition, the physicochemical properties of COM and SAS co-precipitates were also 
compared and discussed.  
 
In Chapter 5, conclusions are drawn to summarize all the important results presented in 
the preceding chapters and recommendations on future research work are given in 
Chapter 6. 
  
                                                                                                                            Chapter 2 
10 
 
2. Literature Review 
2.1 Drug Development and Delivery 
One of the current challenges in drug development and delivery are the discoveries of 
new drug molecules that are poorly water-soluble. More than 90% of drugs approved 
since 1995 have poor solubility, permeability or both [66]. Moreover, more than 40% 
of new chemical entities have little or no water solubility [2]. Therefore, formulation 
strategy and delivery of APIs have played an essential role in the development and 
commercialization of new pharmaceutical products. The main objective of formulation 
chemistry is to improve bioavailability, stability and convenience of the APIs to the 
patient (preferably in solid dosage form). Bioavailability means the rate and extent to 
which the active substance or therapeutic moiety is absorbed from a pharmaceutical 
form and becomes available at the site of action [25]. Moreover, for a drug to be an 
effective for oral treatment, it must be able to dissolve and be absorbed by the blood 
stream. The bioavailability of an orally administered drug depends on its solubility in 
aqueous media over the pH range of 1.0-7.5 and its permeability across membranes of 
the epithelial cells in the gastrointestinal tract (GI). Amidon et al. [66] introduced the 
Biopharmaceutics Classification System (BCS) that divides the active substances into 
four classes as shown in Table 2.1. 
 
Table 2.1 Biopharmaceutics Classification System (BCS) of orally administered drugs 
Class Solubility Permeability 
I High High 
II Low High 
III High Low 
IV Low Low 
 
Class I consists of water-soluble drugs that are well absorbed from the gastrointestinal 
tract and have high bioavailability after oral administration. Drugs in Class II are 
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water-insoluble or slowly dissolving APIs. The absorption of these drugs is 
dissolution-rate limited. In contrast, drugs in Class III dissolve readily but having low 
penetration into bio-membranes of the GI tract. In the case of Class IV (low aqueous 
solubility, low permeability) drugs, oral administration is not recommended.  
 
The oral route of drug administration is the most common and preferred mode of 
delivery because of convenience and ease of ingestion. From a patient’s perspective, 
ingesting a solid dosage form is more comfortable and a familiar ways of taking 
medication. Therefore, patient compliance and thus drug treatment is typically more 
effective with orally administered medications as compared with other routes of 
administration, for example, parenteral. However, there are many newly discovered 
drugs poses problematic and inefficient mode of delivery using oral administration 
route due to its poor aqueous-solubility and bioavailability. Drug absorption into the 
GI tract can be limited by a variety of factors with the most significant contributors 
being poorly water-soluble and/or poor membrane permeability of the drug molecule. 
When delivering API orally, it must first dissolve in gastric and/or intestinal fluids 
before it can then permeate the membranes of the GI tract to reach systemic 
circulation. As a result, a poorly water-soluble drug will generally exhibit dissolution 
rate limited absorption, and a drug with poor membrane permeability will generally 
exhibit permeation rate limited absorption. Therefore, it has heightened the interest of 
pharmaceutical researchers in developing new patents and novel techniques to improve 
oral bioavailability of APIs either in the areas of enhancing solubility and dissolution 
rate of poorly water-soluble APIs or enhancing permeability of poorly permeable drug. 
Hence, in our studies the work is focused on enhancing the dissolution rate of a poorly 
water-soluble drug (BCS Class II) using supercritical anti-solvent (SAS) co-
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precipitation to generate a physically stable solid dispersion as well as with enhanced 
dissolution properties. At the same time, co-milling was also conducted as a 
comparison to SAS process. 
  
2.2 Drug Solubility and Dissolution Rate 
Prior to GI tract absorption, solid oral dosage forms must be disintegrated and 
dissolved into blood stream for effective drug delivery. The dissolution of an API is 
governed by thermodynamic and kinetic factors. The most important thermodynamic 
parameter is the solubility which is the saturation concentration in a given aqueous 
medium at equilibrium. The intrinsic solubility of a specific substance is an inherent 
property and it is temperature dependent. Brittain [67] reported that the measurement 
of intrinsic solubility may take several days or months. However, it is generally 
accepted that to measure the solubility of substance at a meta-stable equilibrium. The 
solubility measured under these conditions is known as apparent solubility and is 
higher than the intrinsic solubility. Normally, the retention time for an API passes in 
digestive system is quite limited and thus, the absorption is governed by kinetic factors 
instead of thermodynamic properties. The dissolution rate is the amount of active 
substance that leaves the surface of drug and dissolved into the solution per unit time. 
Based on the modified Noyes-Whitney equation, the dissolution rate (dm/dt) is 
proportional to the surface area available for dissolution (A), the diffusion coefficient 
of the solute in solvent (D), the concentration across diffusion layer (concentration of 
the solute at saturation (C
S
) - concentration of the drug in the bulk solution (C)) and 






         (2.1) 
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2.3 Formulation Strategies to Enhance Dissolution Rate 
Based on the Noyes-Whitney equation, the dissolution rate can be enhanced through 
increasing diffusivity and decreasing both of the diffusion layer thickness and bulk 
concentration. However, this method requires changing the in-vivo transport 
properties, hydrodynamics and composition of the luminal fluids which is not easily 
attainable. Thus, parameters such as surface area and apparent solubility of the drug 
may be a more feasible way to be manipulated to enhance the dissolution rate. The 
parameter such as surface area can be increased by decreasing the particle size and is 
known as micronization process. 
 
2.3.1 Micronization 
Micronization enhances the dissolution rate of drug by increasing its specific surface 
area (through particle size reduction). The conventional methods for particle size 
reduction are based on mechanical and equilibrium controlled techniques. As for 
mechanical techniques, the dry size reduction of pharmaceutical powders is 
accomplished by impact size reduction. The particle size reduction is commonly 
operated under mechanical impact mills or fluid-energy impact mills. Examples of 
mechanical impact mills are hammer and screen mills, pin mills and air-classifying 
mills. As for fluid-energy impact mills there are spiral jet mills and fluidized bed jet 
mills. A typical impact mills composed of a cylindrical metallic drum filled with 
spherical steel balls and when it rotates the balls inside the drum will collide with the 
particles, thus crushing them into a smaller particle. Fluid-energy impact mills using 
high velocity gas jets to accelerate particles against a hard surface or collision between 
particles with another particles, thus crushing it them into a smaller particle. Milling is 
simple and inexpensive methods for particle size reduction. However, this process may 
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also cause several undesirable effects on APIs such as aggregation of fine particles, 
induction of electrostatic charges, mechanochemical transformation, APIs degradation 
and solid-state reactivity [34-37], and leading to limitation in the use of the milling 
process itself.  
 
Apart of this technique, the equilibrium controlled techniques also is used to improve 
the efficiency of micronization employed by mechanical techniques. The equilibrium 
techniques are based on the sublimation and/or re-crystallization of drug from solution. 
In solution based re-crystallization, drug is dissolved in solution and subsequently 
supersaturation is induced to precipitate the drug to microparticle. There several 
methods to induce supersaturation in a solution such as thermal treatment (heating and 
cooling), evaporation and addition of a third component (anti-solvent, precipitant or 
reactant). Some of these techniques are spray-drying, solvent-evaporation and liquid 
anti-solvent. Rasenack and Muller [69] conducted in-situ micronization of poorly 
water-soluble drug using a controlled crystallization process to generate drug 
microcrystal with enhanced dissolution rate. Steckel et al. [70] compared the physical 
properties and in vitro inhalation behavior of jet-milled, in-situ micronized and 
commercial disodium cromoglycate. The jet-milled powders were electrostatically 
charged and agglomerated into a larger particle. In contrast, the in-situ micronized 
powder has better dispersion and de-agglomeration properties. The mean particle size 
of drug (~3.5μm) was within the respirable range. Recently, Varshosaz et al. [71] used 
in-situ micronization via solvent change method to generate microcrystal of gliclazide. 
The particle size was reduced about 50 times as compared to untreated gliclazide and 
the dissolution efficiency of gliclazide at 15 minutes (DE15%) was increased about 4 
times. Zhang et al. [72] employed anti-solvent and spray-drying processes to micronize 
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atorvastatin calcium to ultrafine powder. The dissolution rate of atorvastatin calcium 
generated using both anti-solvent and spraying processes was improved as compared 
to the raw material. However, these techniques may present several disadvantages, 
such as contamination of the particles with organic solvents or other toxic substances, 
high energy requirement, generation of large volumes of solvent waste and may 
require multiple crystallization steps [73]. 
 
Beneath the conventional methods, new particle design technologies have been 
recently developed to improve the dissolution of APIs. These methods apply new 
concepts based on the use of supercritical fluids or liquefied gases as solvent, anti-
solvent or cryogenic medium [24, 27]. Supercritical fluid (SCF) technology presents a 
new and interesting route for particle formation, which avoids most of the drawbacks 
of the conventional methods (Table 2.2 and Figure 2.1 [74]). A substance is termed as 
a supercritical fluid when it exists as a single fluid phase above its critical temperature 
(Tc) and critical pressure (Pc). The density, viscosity, diffusivity and other physical 
properties (such as solvent strength) of SCF can be varied in a continuum between gas-
like and liquid-like characteristics when it is above its critical points. A commonly 
accepted opinion is that the solvent power of a SCF is mainly related to its density in 
the critical point region. A high density generally implies a strong solvating capacity. 
One of the unique properties of a SCF is its solvating power can be tuned by changing 
either temperature or pressure. Carbon dioxide (CO2) is the most commonly used fluid 
as it is chemically inert, non-toxic and non-flammable. Having mild critical 
temperature (31.1°C) and critical pressure (73.8bar) [75], CO2 is suitable to treat heat-
sensitive APIs such as peptides, DNA and steroids. Particle formations processing 
using supercritical CO2 (Sc-CO2) are subjects of great interest in the pharmaceutical 
                                                                                                                            Chapter 2 
16 
 
and fine chemical industries. Several techniques are available such as rapid expansion 
of supercritical solution (RESS), gas anti-solvent (GAS), supercritical anti-solvent 
solution (SAS), solution enhanced dispersion by supercritical fluids (SEDS) and 
particles from gas-saturated solutions (or Suspensions) (PGSS) to form micronized 
particles using Sc-CO2. A detail discussion on the SCF technologies for particle 
formation is presented in Chapter 2.5. Table 2.3 shows some of the selected particle 
formation using RESS, GAS, SEDS and SAS processes gathered from literature.  
 
Table 2.2 Supercritical fluids versus conventional processes for particles formation 
Disadvantages of conventional processes for particles formation 
Excessive solvent used and disposal. Non-environmentally-friendly. 
Thermal and chemical degradation of products. 
Organic solvent may be present in the product as residual solvent. 
Variability in particle size (broad particle size distribution). 
Advantages of supercritical fluid processes over conventional processes 
Higher diffusivities and lower surface tension result in enhanced mass transfer/reaction rates. It 
allows the formation of particles with controlled size and morphology by controlling the 
pressure and temperature. 
Non-toxic, non-flammable and environmentally-friendly solvents leave no harmful residue 
when using Sc-CO2.  
Ability to rapidly vary the solvent strength and the rate of supersaturation, thus nucleation of 
dissolved compounds. These properties allow it to manipulate the precipitations/reactions and 
aids in product separation. 
The low viscosities of SCF allow it’s recoverable from the extract easily (depressurization). 
Compounds with high boiling points can be extracted at relatively low temperatures. 
Able to process thermolabile compounds.  
Disadvantages of supercritical fluid processes 
High capital investment is required for the equipment. 
Scale-up complexity. 




Figure 2.1 Particle size ranges of different micronization techniques 
 
Table 2.3 Particle formation (micronization) using RESS, GAS, SEDS and SAS  
SCF technique Compound (Solvent)a Particle size References 
RESS Carbamazipine 0.43-0.9μm [76] 
RESS Artemisinin 0.55μm [77] 
RESS Cephalexin 0.9-7.2μm [78] 
RESS Nabumetone 3.3μm [79] 
GAS Insulin (DMSO) < 4µm [80] 
GAS Insulin (DMSO) < 4µm [80] 
GAS Triamcinolone acetonide (THF) 5-10µm [81] 
GAS Poly(L-lactide acid) (DCM) 0.5-3µm [82] 
GAS Griseofulvin (AC) 300-400µm [83] 
SEDS Salmeterol Xinafoate (EtOH, MeOH & AC) 1-10µm [84] 
SEDS Sodium cromoglycate (MeOH) 0.1-20µm [85] 
SEDS Astaxanthin (DCM) 20-30µm [86] 
SEDS Chelerythrine (MeOH) 0.1-1µm [87] 
SAS Cyclotrimethylenetrinitramin (DMSO, DMF, 
ACN, NMP & CHN) 
3-18µm [88] 
SAS 10-hydroxycamptothecin (DCM+EtOH) 0.2-0.3µm [89] 
SAS Erlotinib hydrochloride (MeOH & EA) 2µm [90] 
SAS Indomethacin (DCM & AC) 1-20µm [91] 
a Dimethyl sulfoxide (DMSO); dimethylformamide (DMF); dichloromethane (DCM); methanol (MeOH); ethanol 
(EtOH); ethyl acetate (EA); tetrahyrofuran (THF);  acetone (AC); acetonitrile (ACN); n-methyl 2-pyrrolidone 
(NMP); cyclohexanone (CHN) were used as solvents 
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Unfortunately, the enhancement of dissolution rate of drug attainable by increased 
surface area is quite limited. Therefore, new formulation strategies and techniques that 
can influence the drug physicochemical properties such as dissolution rate, solubility 
and physical stability are currently actively being developed. Some of these techniques 
are solubility enhancers (complexing agents), pro-drugs and various solid form 
formulations. Under the solid form formulations group, some of these formulation 
techniques are to crystallize the drug to different polymorphs, salt formations, co-
crystal formations, solid dispersions with soluble polymers or conversion of the 
crystalline drug to amorphous form [3-5]. Recently, the uses of amorphous forms of 
active pharmaceutical ingredients (APIs) in various solid formulations have received 
considerable attention to enhance/improve aqueous solubility. When a drug substance 
is converted to the amorphous form it lacks of long range molecular order. Therefore, 
amorphous form has higher entropy and enthalpy as compared to its crystalline form. 
The saturated solubility of the amorphous form is higher as compared to its crystalline 
forms due to the higher Gibb’s free energy in amorphous form. Thus, based on Noyes-
Whitney equation increasing in saturation solubility can enhance the dissolution of the 
drug. In the next chapter, the formulation techniques and recent developments on 
amorphous form/solid dispersion material will be reviewed. 
 
2.3.2 Amorphous Form/Solid Dispersion Material 
The solubility of a solid is the sum of crystal packing energy, cavitation and salvation 
energy. Different solid state forms of a material have different crystal packing energy. 
In amorphous form the ordered crystalline lattice is not presence (Figure 2.2B), thus 
providing the maximal solubility advantages as compared to the crystalline and 
hydrated forms of a drug. The apparent solubility and dissolution advantage offered by 
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these systems is a vital approach to enhance bioavailability of poorly water-soluble 
drugs. However, amorphous forms have poor physical and chemical stabilities which 
hurdle its commercialization. One of the possible approaches to overcome these 
challenges is to formulate the drug with polymer/excipient to form solid dispersion. 
Solid dispersion is defined as dispersion of one or more compounds in an inert 
hydrophilic carrier matrix at solid state [92]. For example, it is a molecular mixture of 
drug and hydrophilic polymer (carrier/excipient) in which the dispersed compounds 
may be in individual molecule unities or in clusters, such as in particles [93]. 
 
Currently, there are a few commercial drug products on the market which are based on 
amorphous solid dispersion technology. Some of these products are Novartis's soft 
gelatine capsule Gris-PEG®, which is based on a solid dispersion of griseofulvin in 
polyethylene glycol (PEG 8000) [94]. The Fujisawa's Prograf Creme is based on a 
solid amorphous dispersion of tacrolimus in hydroxypropylmethylcellulose (HPMC) 
[95]. Another amorphous solid dispersion drug product is called Sporanox® 
(itraconazole-HPMC) and is sold as hard gelatine capsules [96]. 
 
 
Figure 2.2 A typical molecular structure of (A) Crystalline; (B) Amorphous form 
 
Solid dispersion is an easier and more feasible approach as compared to chemical 
approach for improving the solubility of poorly water-soluble drugs. Chemical 
approach includes salt formation and formation of pro-drugs [94, 97, 98]. Salt 
formation approach is reported to be associated with limitations such as limited only to 
                                                                                                                            Chapter 2 
20 
 
weakly acidic or basic drugs and not applicable to neutral drugs [93]. In cases of pro-
drug approach, the parent drug moiety must have some specific chemical groups such 
as hydroxyl, carboxylic, amide etc. [99] in order to generate the pro-drug. Generally, 
solid dispersions are found to be more therapeutic compliant by patients than 
solubilization products. In addition, the solid dispersions are more effective in 
improvement the drug release as compared to milling/micronization process due to the 
limitation of particle reduction which is limited typically in the range of 2-5µm. This is 
significantly insufficient to improve the drug absorption in the small intestine [100, 
101]. Moreover, handling of very fine solid powder is extremely difficult because of 
poor mechanical properties such as poor powder flow-ability and high adhesion [102]. 
 
Therefore, the dissolution rate of poorly water-soluble drug could be improved by 
dispersing it in a water-soluble biocompatible carrier such as PVP, polyethylene 
glycol, HPMC, etc., which may inhibit the re-crystallization of the drug [103]. This 
approach leads to composite particle formation such as those obtained from solid 
solution and dispersion technologies for drug substances [21, 51, 104, 105]. The effect 
of a polymer on the re-crystallization rate of amorphous substances is generally 
expressed in terms of properties of the meta-stable amorphous form such as molecular 
mobility, glass transition temperature (Tg) and the interactions arising between the 
drug and the polymer. Substances with higher entropy and enthalpy than the steady 
crystalline form, such as the amorphous or polymorphic forms can be obtained from 
these technologies by modifying the physical structure of the crystals. The amorphous 
state of drug can be stabilized by dissolving the drug into the polymer matrix at 
molecular level and restricting the drug molecules mobility, thus hindering the re-
crystallization process.  
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It is generally understood that polymers improve the physical stability of amorphous 
drugs in solid dispersions by either increasing the Tg of the miscible mixture, thereby 
reducing the molecular mobility at regular storage temperatures, or specifically 
interacting (e.g., hydrogen bonding) with functional groups of amorphous drug 
substance [106-108]. For a polymer to be effective in preventing crystallization by 
these mechanisms, it has to be molecularly miscible with the amorphous substance. 
For complete miscibility, interactions between the two components are necessary 
[109].  
 
A miscible system can phase separate and become unstable if specific interactions 
between the components are adversely affected by a third component like water. The 
extent of moisture uptake depends upon factors like hygroscopicity of the drug and/or 
carrier, the concentration of the active substance in the drug product and the storage 
temperature. Due to this complexity, the prediction of physical stability of a drug 
substance in a solid dispersion becomes challenging. In order for the solid dispersion 
systems to be effectively used by the pharmaceutical industry, it is critical to 
understand the role of time, temperature, humidity in determination of the physical 
stability of solid dispersion during its shelf-life and to establish a robust 
characterization method for amorphous form. Table 2.4 and Figure 2.3 show six types 
of solid dispersions based on their molecular arrangements [110]. The matrix can be 
either crystalline or amorphous. Meanwhile, the drug can be dispersed molecularly, in 
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Table 2.4 Types of solid dispersions 
Type of solid dispersion Matrixa Drugb No. of phases Type 
Eutectics C C 2 I 
Amorphous precipitations in crystalline matrix C A 2 II 
Solid solutions C M 1 or 2 III 
Glass suspension A C 2 IV 
Glass suspension A A 2 V 
Glass solution A M 1 VI 
a A: Matrix in amorphous state; C: Matrix in crystalline state  
b A: Drug dispersed as amorphous clusters in the matrix; C: Drug dispersed as crystalline particles in the matrix; M: 







Figure 2.3 Schematic diagrams of six types of solid dispersions 
 
Solid dispersions are commonly prepared by three different methods such as solvent 
evaporation method, fusion-melt method, and hybrid fusion-solvent evaporation 
method [93]. Some of these techniques are solvent deposition [17], co-milling (COM) 
[14, 19, 111], melt-extrusion [20, 21], spray-drying [22], melt-quenching [23] and 
supercritical fluids technology [24-27]. Table 2.5 shows several techniques used to 
generate amorphous forms of drugs gathered from literature.  
 
Among the various techniques that can generate amorphous form/solid dispersion, 
milling is a common unit operation employed for particle size reduction which is 
relatively low-cost and easily scalable manufacturing processes. Therefore, one of the 
aims of this study is to compare the effectiveness of a low-cost and easily scalable 
process [28, 29] co-milling (COM) with high-cost and precise-controlled [112-114] 
    Crystalline particle                Amorphous particles            Molecularly dispersed 
      (Type I and IV)                   (Type II and V)                (Type III and VI) 
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supercritical an-solvent (SAS) co-precipitation process to amorphize IDMC with PVP 
to improve its physical stability and enhance the dissolution rate of IDMC.  
 
Table 2.5 Techniques to generate amorphous materials 
Technique Possible associated problems   Reference 
Mechanical stress 
(milling, co-milling) 
Dependent on crystal structure 
Crystal seeds may presence in formulation 
May not suitable for thermolabile material 
Milling time dependence  
 [6, 14, 19, 53, 
111, 115, 116] 
Spray-drying Energy consumption 
Residual solvents 
Many process parameters 
May require high temperature 
[22, 117] 
Melt extrusion High temperature 
High amount of excipients may be required 
Not suitable for thermolabile material 
[20, 21, 118] 
Freeze-drying  Energy consumption 
Residual solvents 
Slow process 
Many processing steps 
[119, 120] 
Melt quenching High temperature 
Chemical degradation 
Cooling is needed 
Energy consumption 
[6, 23, 115, 116] 
Vapour deposition Chemical degradation [121] 
Vacuum systems Residual solvents [122] 
SCF technologies High pressure 
Scale-up complexity 





Dehydration of  
hydrated crystals 
Limited to some hydrated crystals [124] 
High pressure compaction Energy consumption 








In order to improve the milling efficiency, a favourable method using co-milling 
(Figure 2.4) of drug with additives has been successfully applied [19, 36, 38]. 
Stabilization of amorphous form generated using co-milling or co-grinding with 
amorphous excipients such as PVP, magnesium aluminometasilicate (Neusilin US2), 
etc., has been successfully employed [18, 126]. Several authors [13, 18, 127, 128] have 
studied the physical stabilization of amorphous IDMC by co-grinding with silicates. 
The effect of mass ratios of IDMC to Neusilin US2 and processing humidity on 
stabilizing the amorphous form of IDMC were studied by Bahl and Bogner [18]. 
Plasticization of amorphous drug to allow mechanical transfer of drug to silicate, 
vapour phase mass transfer, and the role of water in particle–particle surface migration 
of the drug to the silicate have been put forward as possible explanations for the 
formation of the stable IDMC–silicate alloy. 
 
Figure 2.4 A typical co-milling of drug with polymer to generate amorphous material 
 
Mura et al. [129] conducted co-milling of glisentide with PVP and studied the 
physicochemical properties of the co-milled samples. The amorphous state of co-
milled sample was the main factor for obtaining 100% dissolution efficiency increase 
as comparison to the untreated drug. The dissolution rate increased with PVP content 
in the co-milled sample. Moreover the milling time to fully amorphize glisentide with 
PVP was reduced with increase of PVP ratios [129]. Chieng et al. [130] investigated 
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the physicochemical properties and stability of co-milled IDMC with various weight 
ratios of ranitidine hydrochloride. They reported the stability of the amorphous binary 
system (1:1) was found to be stable after 30 days of storage at 4 and 25oC. Recently, 
Lobmann et al. [131] using co-milling to generate various weight ratios of co-
amorphous drug-drug from simvastatin (SVS) and glipizide (GPZ). It was found that 
even though a molecular mixture was achieved with all SVS–GPZ mixture ratios, no 
molecular interactions between the drugs could be detected. By formation of co-
amorphous single-phase mixtures, only the dissolution rate of GPZ could be improved. 
The co-amorphous mixtures showed improved stability compared to the pure 
amorphous forms and the amorphous physical mixtures, respectively. It was concluded 
that this was attributable to the molecular level mixing of SVS with GPZ upon milling, 
and GPZ is acting as an anti-plasticizer in these mixtures. Wang et al. [132] 
investigated the physical stability and dissolution rate of co-milled ibuprofen with β-
cyclodextrin. The solubility of co-ground complex was more than ten times higher 
than that of intact drug. The amorphous state of the co-ground complex was the main 
responsible factor for the enhanced dissolution efficiency of drug. The result also 
showed that at 25, 40 and 55°C, the co-ground complex was stable below 74%RH 
[132]. 
 
2.5 Supercritical Fluids Technologies 
For pharmaceutical applications, the most preferable supercritical fluid is using CO2, 
which is used as either a solvent for drug and polymer matrix or act as an anti-solvent 
[133, 134]. When supercritical CO2 is used as solvent, the drug and polymer matrix are 
dissolved into supercritical CO2 (Sc-CO2) and sprayed through a nozzle into an 
expansion vessel with lower pressure to form particles. The adiabatic expansion of the 
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mixture caused a rapid cooling in the surrounding of the vessel. This technique is 
known as “solvent free” process as it does not require the use of organic solvents and 
also CO2 is considered as an environmentally-friendly solvent. The technique is known 
as rapid expansion of supercritical solution (RESS). However, the application of this 
technique is quite limited, because the solubility of most pharmaceutical compounds in 
CO2 is very low (<0.01wt.%) [49] and decreases with increasing polarity. As a result, 
the process scale-up for RESS to kilogram-scale may not be practically feasible.  
 
The other supercritical techniques are using Sc-CO2 as anti-solvent to precipitate the 
drug into particles. Although generally labeled as solvent-free, all these supercritical 
fluid methods used organic solvents to dissolve drug and polymer matrix to overcome 
the low solubility of APIs in Sc-CO2. These techniques also served as alternative 
methods to remove solvents from a solution containing typically a drug and a polymer. 
Moneghini et al. [135] used gas-anti-solvent technique (GAS) or precipitation from gas 
saturated solutions (PGSS) on dissolved polyethylene glycol and carbamazepine in 
acetone and reported this method as solvent-free. In this process, the solution is 
brought into contact with compressed CO2. A process condition is chosen in order for 
CO2 to be completely miscible with the solution under supercritical conditions but the 
drug and polymer matrix will precipitate upon expansion of the solution. When the 
volume of the solution expands, the solvent strength (i.e. the ability to dissolve the 
drug) decreases and causes the polymer matrix and drug to co-precipitate as particles.  
 
Another type of precipitation technique utilizes the spraying of a solution containing 
drug and polymer matrix through a nozzle into a vessel filled with liquid or 
supercritical anti-solvent. The high mass transfer rate and mixing between the 
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supercritical anti-solvent and solution droplets causes the solution containing drug and 
polymer matrix become supersaturated and subsequently co-precipitates as particles. 
The general term for this process is known as precipitation with compressed anti-
solvent (PCA) [49]. More specific examples of PCA are supercritical anti-solvent 
(SAS) or aerosol solvent extraction system (ASES), and solution enhanced dispersion 
by supercritical fluids (SEDS) [49, 133]. There is another process called supercritical 
fluid impregnation, the drug is dissolved in a supercritical fluid and exposed to a solid 
polymer matrix that swells and absorbs the supercritical solution. By varying the 
pressure and the time of exposure, the diffusion process can be controlled. The 
absorption stops when the pressure is reduced. Vincent et al. [136] investigated 
supercritical fluid impregnation process using poly(methyl methacrylate) and reported 
that this process can be applied to other polymers as well. A more detail discussion on 
RESS, PGSS, SAS and SEDS processes are presented in subsequent chapters (2.5.2-
2.5.4). 
 
2.5.1 Physicochemical Properties of Supercritical Fluids 
A general discussion on the physicochemical properties of supercritical fluid is 
presented in this section. Figure 2.5 shows the phase diagram of CO2 [137]. The 
equilibrium phase boundaries for two phases to co-exist are represented by “red curve-
lines” on the pressure-temperature diagram. The triple point is the state of all three 
phases co-existence in equilibrium. A substance is defined as a supercritical fluid when 
both of its pressure and temperature exceeded its critical pressure (Pc) and temperature 
(Tc). At the critical point, there is no distinction between the phases. Moreover, by 
lowering the pressure or the temperature in the supercritical fluid region will change 
the substance state into vapour or the liquid region, respectively, without any phase 
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change occurred during the transition. Supercritical fluid acquires unique properties of 
a good solvent and the solubility of solid solutes/co-solvents in supercritical fluid, 
which is dependent to pressure and temperature. The degree of freedom of variables is 
1 on the phase boundary line and 0 on the triple point and critical point, whereas 
outside these lines it is 2 (e.g. pressure and temperature) according to Gibbs phase rule. 




Figure 2.5 Phase diagram of carbon dioxide 
 
Table 2.6 Critical constants of typical substances used as SCF solvents 
Substance Critical temperature Tc (K) 
Critical pressure 
Pc (bar) 
Critical compressibility factor 
Zc 
Argon 151 49 0.296 
Methane 191 45 0.287 
Xenon 290 58 0.287 
Carbon dioxide 304 73 0.274 
Ethane 305 48 0.285 
Propane 370 42 0.281 
Ammonia 406 111 0.244 
Water 647 218 0.235 
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When a pure substance (e.g. CO2) is at supercritical fluid region, the changes of its 
transport properties such as density, viscosity, thermal conductivity, surface tension 
and constant-pressure heat capacity are significant as shown in Figure 2.6 [138-140]. 
Sc-CO2 displays a liquid-like density that is tunable with pressure, a gas-like 
diffusivity, and a viscosity that is quite low which is about 1/10 that of water [141] 
(Table 2.7). These properties make Sc-CO2 an attractive option to replace traditional 
organic solvents and anti-solvents that are often volatile organic compounds (VOCs). 
SCF exploits the dramatic increase in density and thus solvent strength of CO2 at 
pressures above the critical pressure. Moreover, SCFs exhibit almost zero surface 
tension, which allows easy penetration into microporous materials. The combination 
advantageous of these physicochemical properties allows the extraction process to be 
conducted more efficiently using SCF than organic liquid solvent. High solute loading 
can be achieved for non-polar substances, while polar and complex molecules are often 
only sparingly soluble in Sc-CO2, even at very high pressures.   
 





coefficient (D11)  
Density (ρ)  
Viscosity (η)  
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Table 2.7 Density and viscosity of gases, liquids and SCFs 
Physical state Density (g/cm3) Viscosity (g/cm·s) 
Gas 10-3 10-4 
SCF 0.2-0.9 10-4-10-3 
Liquid 0.7-1.0 10-2 
 
2.5.2 SCF as Solvent Process 
2.5.2.1 RESS Process 
The rapid expansion of supercritical fluids (RESS) process takes advantage of SCF 
solvent power tunability with changes in pressure [142]. As shown in Figure 2.7, the 
RESS consisted of a two-step process (extraction and precipitaion). The first step is an 
extraction in which the supercritical fluid is saturated with the substrates of interest. 
This extraction is followed by a sudden depressurization in a nozzle (typically 10-
50µm internal diameter) which drastically decreases the solvent power and the 
temperature of the fluid and causing the solute to precipitate as microparticles [143]. 
The decrease in the solvent power of the SCF due to the depressurization is of several 
orders of magnitude, leading to supersaturations which typically are in the range 105–
106. This supersaturation is produced by a mechanical perturbation which is 
propagated at the velocity of the sound, in a time scale usually of 10−6–10−4s. 
Therefore, this process could achieve extremely high supersaturations which are 
transmitted very quickly and homogeneously to the whole fluid, thus leading to the 
formation of small particles with narrow PSD. Additionally, the process can be 
performed at moderate temperatures (typically below 80°C) which is suitable for heat-
sensitive products and no organic solvents are required.  
 
However, it is well known that the main limitation of this method is that it is only 
applicable to substances with relatively high solubility in the SCF, mainly non-polar 
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compounds or volatile polar compounds such as alcohols or esters, while non-soluble 
compounds such as acids or salts might not be easily processed [27, 144]. Even in the 
most favorable cases the production capacity of the process is often limited. This 
problem can be alleviated by the use of a co-solvent [27]. Mishima et al. [145] 
invented a new method called rapid expansion from supercritical solution with a non-
solvent (RESS-N) to overcome the difficulties associated with SCF-insoluble polar 
compound. This process used a polymer dissolved in a SCF containing a co-solvent 
and sprayed through a nozzle to atmospheric pressure. The co-solvent increases the 
solubility of the API of interest significantly in Sc-CO2, but API is immiscible with the 
co-solvent [146]. 
 
Figure 2.7 Schematic diagram of RESS process 
 
Debenedetti et al. successfully co-precipitated lovastatin and pyrene with poly (L-lactic 
acid) [147, 148]. Perrut et al. [149] used RESS co-precipitation process on three poorly 
water-soluble APIs (nifedipine, lidocaine and sulfathiazole) with hydrophilic block co-
polymer poloxamer 188 and investigated its dissolution rate profiles. The co-
precipitates improved the dissolution rate of nifedipine and lidocaine but not 
sulfathizole. Recently, Vemavarapu et al. [150] investigated co-precipitation of APIs 
and their structurally related additives using RESS process. Amorphous forms of co-
CO2 
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precipitates of indomethacin-salicylic acid and naproxen-α-napthelene acetic acids 
were successfully generated. Table 2.8 shows some of co-precpitates generated using 
RESS/RESS-N process gathered from literature.  
 
Table 2.8 Co-precipitation process using RESS/RESS-N 
Material 1 Material 2a Co-solvent Reference 
Naproxene L-PLA  - [151] 
Β-sitosterol Eudragit - [152] 
Flurbiprofen Lactose - [153] 
Lipase PEG, PLA EtOH [146]a 
Lysozyme PEG, PMMA EtOH  
p-Acetomidophenol PEG MeOH, AC, C3H7OH [154]b 
Acetylsalicylic acid PEG EtOH  
Flavone PEG EtOH  
a L-Poly (lactic acid) (L-PLA); Poly (ethylene glycol) (PEG); Poly (methyl methacrylate) (PMMA) 
b Using RESS-N process 
 
2.5.3 SCF as Solute Process 
2.5.3.1 PGSS Process 
The particles from gas saturated solution (PGSS) process does not utilize the properties 
of SCF as a solvent or as an anti-solvent, but using the cooling effect produced from 
depressurization of SCF at supercritical conditions to ambient pressure. In the PGSS 
process (Figure 2.8), SCF is dissolved in a melted solid, and the mixture is rapidly 
expanded through a nozzle and causing the solution to precipitate as particles. Sencar-
Bozic et al. [155] reported that the consumption of CO2 in PGSS method is lower than 
RESS method by an order of magnitude of 103. This process is useful for substances 
such as polymers due to high solubilty of CO2 in most polymers. Moreover, this 
process is also useful to polymer because of the absorbed Sc-CO2 in the polymer 
matrices reduces the melting/glass transition temperature of polymer. 




Figure 2.8 Schematic diagram of PGSS process 
 
The PGSS method has been succesfully applied for a mixture of APIs and polymer to 
generate co-precipitated particles [155, 156]. Sencar-Bozic et al. [155] applied the 
PGSS method to micronize nifedipine. They also co-precipitated nifedipine with 
polyethylene glycol (PEG) (MW=4000) using PGSS. Both co-precipitates and 
micronized nifedipine have improved the dissolotion rate of nifedipine as compared to 
the raw material. Kerc et al. [157] also applied the PGSS technique to micronize two 
poorly water-soluble drugs (felodipine and fenofibrate) and co-preciptated both drugs 
with PEG to increase their dissolution rate. They reported that dissolution rate was 
improved using PGSS co-precipitation of drugs with PEG as compared to the raw 
material. They reported that the improved dissolution rate of felodipine was related to 
both particle size reduction and drug–polymer interactions [157]. 
 
2.5.4 SCF as Anti-solvent Processes (GAS, SAS and SEDS) 
2.5.4.1 GAS Process 
Gas anti-solvent (GAS) process is a complementary to RESS process. The GAS is a 
batch precipitation process that exploits the low solubilities of polar compounds and 
polymers in Sc-CO2 (Figure 2.9). Firstly, a solution is made of the solute in an organic 
solvent and pressurized with CO2. This process typically operates at moderate 
pressures (50–80bar). In this operating range, the CO2 can dissolve /miscible with most 
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organic solvents but has poor solvent power on high molecular weight substrates. 
Therefore, the saturation of the organic solvent with CO2 causes a decrease in the 
solvent power of the liquid mixture and causing the solute to precipitate as 
microparticles. Due to the high solubility of CO2 in the liquid phase and the favorable 
transport properties, the kinetics of the mixing process are enhanced with respect to the 
mixing with conventional liquid anti-solvents, leading to more homogenous 
supersaturations. Thus, the particle size and morphology can be controlled by the rate 
and method of CO2 addition [158]. Besides that, the liquid phase can be easily 
separated by depressurization and both the solvent and CO2 can be recycled. 
 
Moneghini et al. [135] applied the GAS method to co-precipitate carbamazepine 
(CBZ) with PEG (MW=4000). CBZ is practically insoluble in water and PEG 
increases the solubility of CBZ in water due to its hydrophilic characteristic. They 
reported that the dissolution rate of CBZ was improved by increasing PEG 
concentration in CBZ-PEG co-precipitate. Recently, Subra-Paternault et al. [159] co-
precipitated a poorly water-soluble drug (tolbutamide) with micrometric silica and 
biopolymers (PEG and Eudragit) using batch GAS process. They reported that the 
products exhibited substantially different rates of dissolution in accordance with the 
polymer function. The water-soluble PEG-tolbutamide co-precipitates improved the 
dissolution rate of tolbutamide as compared to the raw drug. A controlled release of 
tolbutamide was observed using water-insoluble Eudragit-tolbutamide co-precipitates. 




Figure 2.9 Schematic diagram of GAS process 
 
2.5.4.2 SAS Process 
The semi-continuous supercritical anti-solvent (SAS) processes were developed in 
order to overcome the limitations in the production capacity of the batch GAS 
processes. In SAS process, the Sc-CO2 and the organic solution (containing 
solute/drug) are continuously fed into the precipitation chamber in a co-current flow 
using different nozzles (Figure 2.10). Supersaturation is induced by the mutual 
diffusion of the Sc-CO2 (anti-solvent) into the solution and the solvent into the bulk 
phase, thus caused solute/drug to precipitate as micronized particles (Figure 2.11). The 
CO2 and organic solution are continuously vented from chamber and/or recovered. The 
precipitated solids were accumulated inside the vessel and were collected at the end of 
the operation.  
 
Figure 2.10 Schematic diagram of SAS process 





Figure 2.11 Schematic representation of SAS process 
 
Won et al. [160] investigated the physicochemical characteristics of solid dispersions 
of felodipine with hydroxypropylmethylcellulose (HPMC) and surfactants generated 
using conventional solvent evaporation (CSE) and SAS process. They also studied the 
effects of the drug/polymer ratio and surfactants on the solubility of felodipine. The 
physical state of felodipine transformed from crystalline to amorphous form 
(DSC/XRD data) during the CSE and SAS processes. In rank order of dissolution rate, 
the SAS solid dispersions have the highest dissolution rate followed by CSE solid 
dispersions and its physical mixtures. Moreover, the solubility of felodipine increased 
with decreasing drug/polymer ratio or increasing surfactant content [160]. Rodier et al. 
[161] applied a new three-step process (co-precipitation, maturing and stripping) based 
on supercritical anti-solvent technology to co-precipitate eflucimibe with cyclodextrin. 
The main novelty of this process lies in the coupling of these three steps, exhibiting a 
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strong synergistic effect in the improvement of the dissolved drug concentration of the 
drug.  
 
Chang et al. [162] applied SAS process to micronize sulfamethoxazole (poorly water-
soluble drug) and co-precipitate it with hydroxylpropylcellullose (HPC). They reported 
that SAS co-precipitation of sulfamethoxazole with hydrophilic polymer HPC 
enhanced dissolution rate of sulfamethoxazole as compared to the SAS micronized and 
raw sulfamethoxazole, respectively. SAS co-precipitation of cefuroxime axetil (CFA, 
antibiotic, amorphous form) with poly(vinylpyrrolidone) (PVP-K30) was performed 
by Uzen et al. [163]. However, the drug release rate of SAS-co-precipitated CFA-PVP 
(1:1w/w) particles was almost 10 times slower than the drug alone. As the ratio of the 
polymer increased, the dissolution rate of CFA of SAS-CFA-PVP co-precipitates was 
higher than the raw CFA due to the increased wetting effect of PVP. Recently, De 
Zordi et al. [164] generated solid dispersion of furosemide with crospovidone using 
SAS co-precipitation process. The physicochemical characterization of SAS-
Furosemide-crospovidone solid dispersions (1:1 and 1:2 wt./wt., respectively) revealed 
the presence of the drug amorphously dispersed in the 1:2 wt./wt. samples at 100bar 
and remained stable after 6 months of storage. The SAS solid dispersion exhibits the 
best in vitro dissolution performance in the simulated gastric fluid (pH 1.2), in 
comparison with the same solid dispersion obtained by conventional methods. Thus, 
the drug to polymer ratio plays a crucial role in the generation of co-formulation. A 
balance between drug and polymer/excipient in the final co-formulation should be 
attained to ensure sufficient shelf life and drug therapeutic efficacy. However, this 
optimization requires more understanding on the drug-polymer thermodynamic system 
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and the nature of amorphous character, which has not been well reported. Table 2.9 
shows some of co-precipitates generated using SAS process gathered from literature. 
 
Table 2.9 Co-precipitation process using SAS 
Material 1 Material 2a Material’s solventb Reference 
Carotenoid PEG DCM [165] 
Indomethacin, piroxicam & thymopentin L-PLA  DCM [166] 
Lysozyme PGLA  DCM [167] 
Diuron L-PLA  DCM [168] 
Diuron L-PLA  DCM [169] 
 PMMA  DCM & THF  
 PMMA  DCM  
 EC  DCM  
 CA  THF  
Insulin L-PLA  DMSO + DCM [170] 
Hydrocortisone PVP EtOH [171] 
a L-Poly(lactic acid) (L-PLA); Poly(ethylene glycol) (PEG); Poly(methyl methacrylate) (PMMA); Ethylene 
cellulose (EC);Poly(lactic-co-glycolic acid) (PGLA); Cellulose acetate (CA)  
b Dichloromethane (DCM); Tetrahydrifuran (THF); Dimethyl sulfoxide (DMSO) 
 
2.5.4.3 SEDS Process 
Solution enhanced dispersion by supercritical fluids (SEDS) represents a specific 
implementation of the GAS and SAS processes. These supercritical anti-solvent 
techniques (SAS, GAS and SEDS) share the same particle formation principles and 
differ in the manner in which the solution is contacted with the SCF. In the SEDS 
process (Figure 2.12), both the solute solution and the anti-solvent are fed into the 
precipitation chamber through a co-axial nozzle. The solute dissolved in an organic 
solvent flows through the center inner tube, and the anti-solvent, typically CO2, flows 
through the outer tube. This co-axial configuration allows rapid mixing (mass transfer) 
of the streams in the nozzle, where the CO2 dissolves into the solution droplets and the 
solvent is dissolved into the CO2-rich phase. The SEDS was invented and patented by 
Hanna and York [84].  
 




Figure 2.12 Schematic diagram of SEDS process 
 
The formation of solid solution particles in the SEDS process from a model drug and 
two different types of carriers, mannitol and eudragit was investigated by Juppo et al. 
[172]. They reported that SEDS co-precipitation generated solid solution of the drug 
with eudragit only. FTIR analysis of the co-precipitate showed that interaction existed 
between the acid hydroxyl group of the drug and the basic carbonyl group on the 
eudragit. Jun et al. [173] applied SEDS process to co-precipitate cefuroxime axetil 
with HPMC or PVP (K-30) to increase the dissolution rate of the drug. The SEDS co-
precipitates were in amorphous form and significantly improved the dissolution rate of 
the drug as compared to its physical mixtures and raw drugs, respectively. Toropainen 
et al. [174] generated solid budesonide-γ-cyclodextrin complexes using a single-step 
SEDS process. The dissolution rate of this complexed budesonide was significantly 
higher as compared to unprocessed micronized budesonide and SEDS-processed 
budesonide without γ-cyclodextrin, respectively. Recently, Li et al. [175] compared the 
physicochemical properties of the phospholipids complex of puerarin prepared by 
conventional methods (solvent evaporation, freeze-drying and micronization) and SCF 
technologies (GAS and SEDS). Phospholipids complex prepared using supercritical 
fluid technologies showed similar properties of physical state, thermal stability and 
molecular interaction with phospholipids to those of corresponding systems prepared 
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by other three conventional methods (based on XRD, DSC, and FTIR). The best 
dissolution rate was obtained by SEDS-prepared complex, while the highest solubility 
was obtained using solvent evaporation method. Table 2.10 shows some of co-
precpitates generated using SEDS process gathered from literature. 
 
Table 2.10 Co-precipitation using SEDS 
Material 1 Material 2a Material’s solventb Reference 
Gentamycin, naltrexone & rafampin L-PLA DCM [176] 
Hydrocortisone DL-PLG  DCM [177] 
Plasmid DNA Mannitol H2O+IPA [178] 
Budesonide PLA  DCM [179] 
a L-Poly(lactic acid) (L-PLA); Poly(D,L-lactide-co-glycolide) (DL-PLG) 
b Dichloromethane (DCM); Isopropanol (IPA) 
 
2.6 Characterizations of Solid Dispersion 
Currently, the generation of amorphous drug in large scale still posed a problem to the 
pharmaceutical industry [115]. Moreover, the characterization methods of 
physicochemical properties of amorphous form are still lacking due to the 
characterization methods mainly focused on detecting the presence of crystalline rather 
than presence of amorphous state [115, 116]. Therefore, there are many 
characterization methods used to detect amount of crystalline material in the 
dispersion. The amount of amorphous material is not measured directly but is mostly 
derived from the amount of crystalline material in the sample [115]. As a result, the 
derived amorphous content of drug does not provide any information whether the drug 
is present as amorphous drug or as molecularly dispersed molecules (Figure 2.3) 
through the assessment of crystallinity characterization method. In some case, the 
amorphous drug system was classified as amorphous form although the drug may exist 
as liquid crystals due to the inadequate of physicochemical characterizations [180].  
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The properties of a solid dispersion are highly affected by the uniformity of the 
distribution of the drug in the matrix. The stability and dissolution behaviour could be 
different for solid dispersions that do not contain any crystalline drug particles which 
are the solid dispersions of type V and VI or for type II and III (Figure 2.3). However, 
not only the knowledge on the physical state (crystalline or amorphous) is important 
but the distribution of the drug as amorphous or crystalline particles or as separate drug 
molecules is relevant to the properties of the solid dispersion too. Nevertheless, only 
very few studies focus on the discrimination between amorphous incorporated particles 
versus molecular distribution or homogeneous mixtures [181, 182]. In this section, a 
brief discussion on some of the currently used characterization methods will be 
highlighted.  
 
2.6.1 X-ray Powder Diffraction (XRD) 
X-ray powder diffraction (XRD) can be used to qualitatively detect material with long 
range order. XRD also is the most convenient method for evaluating whether the 
formulation is in the amorphous state. In amorphous state, the XRD measurement 
provides a halo diffraction pattern. A sharp and distinct diffraction peaks indicates a 
crystalline material. However, it should be stressed that nuclei and small crystals 
cannot be detected using the XRD technique. Recently, the new XRD equipment is 
capable to provide semi-quantitative analysis. 
 
2.6.2 Scanning and Transmission Electron Microscopy  
Scanning electron microscopy (SEM) and transmission electron microscopy (TEM) 
can be used to evaluate the differences between molecularly dispersed drug and/or 
nano-dispersion in amorphous solid dispersion with the aid and complementary to 
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XRD [183]. The hot stage microscopy can be used to characterize the physical 
properties of materials as a function of temperature, evaluation crystal forms, hydrates 
and other physicochemical properties [184]. 
 
2.6.3 Differential Scanning Calorimetry (DSC) 
Differential scanning calorimetry (DSC) and Hyper-DSC can be used to evaluate the 
temperatures at which thermal events like glass to rubber transition, re-crystallization, 
melting or degradation. Melting energy (enthalpy of fusion) can be used to detect the 
amount of crystalline material. Re-crystallization energy can be used to calculate the 
amount of amorphous material, and also provide the information whether all 
amorphous material is transformed to the crystalline state or not [184]. Isothermal 
microcalorimetry also could be used to measure the crystallization energy of 
amorphous material that is heated above its glass transition temperature (Tg) [185]. 
However, this technique has some limitations. Firstly, this technique can only be 
applied if the amorphous material re-crystallized during the measurement. Secondly, it 
has to be assumed that all amorphous material crystallizes. Thirdly, in a binary mixture 
of two amorphous compounds a distinction between crystallization energies of drug 
and matrix is difficult. Besides that, temperature modulated differential scanning 
calorimetry (TMDSC) can be used to access the amount of molecularly dispersed drug. 
Subsequently, the fraction of drug that is dispersed as separate molecules can be 
calculated [186]. 
 
2.6.4 Physical Stability Evaluation 
Physical stability is the most challenging issue to overcome for solid dispersions. 
During long-term storage, the rate-limiting step of crystallization is nucleation [187]. 
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However, the temperature dependence of the nucleation rate is difficult to evaluate, 
and nucleation occurs in a whimsical manner. An accurate estimation of the 
crystallization rate during storage can be done only by observing the stability at the 
same temperature of the storage conditions. Thus, much effort is ongoing to establish a 
protocol for predicting long-term physical stability [12, 188]. One of the commonly 
used methods to evaluate physical stability of solid amorphous form is based on the 




 Table 2.11 ICH guidelines for stability testing of new drugs and products  
Stability study Storage condition Minimum storage period 




Intermediateb 30oC±2oC/65%RH±5%RH 6 months 
Accelerated 40oC±2oC/75%RH±5%RH 6 months 
a It is up to the applicant to decide whether long term stability studies are performed at 25 ± 2°C/60% RH ± 5% RH 
or 30°C ± 2°C/65% RH ± 5% RH 
b If 30°C ± 2°C/65% RH ± 5% RH is the long-term condition, there is no intermediate condition 
 
2.6.5 Gravimetric Vapour Sorption (GVS) 
Water vapour sorption can be used to discriminate between amorphous and crystalline 
material when the hygroscopicity is different [189]. This method requires accurate data 
on the hygroscopicity of both completely crystalline and completely amorphous 
samples. Young et al. [190] applied organic dynamic vapour sorption (organic-DVS) 
to characterize amorphous content in known amorphous-crystalline mixtures of lactose 
and salbutamol sulfate. Recently, Sheng et al. [191] employed gravimetric vapour 
sorption (GVS) to induce the re-crystallization behavior of amorphous etravirine. 
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2.6.6 Fourier Transformed Infrared and Raman Spectroscopy 
Infrared spectroscopy (IR) can be used to detect the variation in the energy distribution 
of interactions between drug and polymer matrix [192]. Sharp vibrational bands 
indicate crystallinity [193]. Fourier transformed infrared spectroscopy (FTIR) was 
used to accurately detect crystallinities ranging from 1-99% in pure material [107]. 
However, in solid dispersions only qualitative detection was possible [194]. Confocal 
Raman spectroscopy can be used to evaluate the content and homogeneity of the solid 
mixture in the solid dispersion [181]. Recently, Widjaja et al.[195] employed Raman 
microscopy and chemometric analysis to detect trace of crystallinity in four different 
amorphous systems. They also reported that the spatial distributions of drug and 
polymer can be directly obtained in order to study the homogeneity of the APIs in the 
solid dispersions. 
 
2.6.7 Inverse Gas Chromatography (IGC) 
It is often known that re-crystallization started to occur at the surface of amorphous 
materials. Crowly and Zografi [63] reported that smaller particles of amorphous IDMC 
and IDMC-PVP solid dispersion re-crystallized faster as compared to the larger 
particles, indicating surface-mediated nucleated occurred. Therefore, the surface 
properties of powders are important parameter in the handling and performance of a 
wide range of solid materials.  
 
Recently, inverse gas chromatography (IGC) is used to study the surface and bulk 
properties of particulate and fibrous materials. IGC has been used to measure 
physicochemical properties of solid materials such as powder surface energies, 
acid/base/polar functionality of surfaces and phase transition temperatures/humidities. 
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In addition kinetic effects such as diffusion and permeability may also be measured. 
IGC is a vapour sorption technique in which the powder is packed in a column and 
known vapours (usually at infinite dilution in a carrier gas) are injected. From the 
retention times of the probes it is possible to assess the surface nature of the material in 
the column. In keeping with the calorimetric and gravimetric techniques, it is to be 
expected that this vapour sorption approach will also be able to detect differences in 
samples due to small amounts of amorphous content. In summary, IGC is an excellent 
tool for studies of transitions in the amorphous state, probing critical surface changes, 
revealing conditions where physical transitions occur and doing this in defined 
conditions. 
 
Hellen et al. [196] employed the IGC to assess the differences in surface energy 
(crystalline, amorphous and milled lactose) due to processing induced disorder and to 
understand whether the disorder dominated the surfaces of particles. They reported that 
materials with small amount of amorphous content can have very different surface 
energies as compared to the crystalline form. 
 
Buckton et al. [197] investigated the glass transition temperature of a powder surface 
using IGC. They reported that it possible to better understand the slow and complex 
changes that occur in hydrophobic amorphous materials as a function of temperature 
and relative humidity using IGC. Ohta and Buckton [198] used IGC to assess the acid-
base contributions to surface energies of cefditoren pivoxil and methacrylate co-
polymers and the possible link to instability. They reported that the IGC would be 
suitable to elucidate the cause of incompatibility between two different solids. 
Hasegawa et al. [64] employed IGC to determine the structural relaxation at the 
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surface of amorphous solid dispersion. They reported that the structural relaxation at 
the surface happens faster than that of the bulk solid. Recently, Ke et al. [65] 
investigated the preparation methods on surface/bulk structural relaxation and glass 
fragility of amorphous solid dispersions using IGC.  They also reported that the surface 
had higher molecular mobility than the bulk solid. 
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3. Material and Methods 
3.1 Model Compound 
γ-Indomethacin (1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid), IDMC 
(Fluka) and poly(vinylpyrrolidone), PVP (molecular weight 360,000, Sigma) were 
used as received. IDMC, a poorly water-soluble (<0.01µg/mL in water from Merck 
Index, 2006) and non-steroidal anti-inflammatory drug (NSAID), which is classified as 
class II drugs in Biopharmaceutical Classification System (BCS) has low 
bioavailability and high permeability. IDMC is used as a painkiller and treating 
inflammatory conditions such as arthritis, osteoarthritis, alkylosing spondylitis and 
other disorders. It has a molecular weight of 357.79g/mol.  
 
IDMC existed in two known polymorphic forms of α and γ-indomethacin. The γ-phase 
(triclinic, plate morphology) constituting the monotropic system and is the 
thermodynamically more stable form than α-phase (monoclinic, acicular habit) [199]. 
In the monoclinic form, 6 molecules of IDMC with three different conformations are 
packed in a unit cell, whereas for a unit cell of the triclinic form, two molecules of the 
same conformation and dimerization is formed by hydrogen bonding between 
carboxylic acid functional groups [200]. The melting point of the α-form is 155oC with 
a heat of fusion of 91J/g, whereas the γ-form melts at 161oC with a heat of fusion of 
110J/g [200]. The decomposition temperature of IDMC is 220oC [200]. 
 
PVP is an amorphous polymer with MW ranging from 2,500 to 3,000,000. It is 
classified according to the K value, which is calculated using Fikentscher's equation 
[201]. Glass transition temperature (Tg) of PVP is high and depends on molecular 
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weight and moisture content. The high Tg of PVPs (>160oC) may renders them 
unsuitable for the preparation of solid dispersions by the hot melt method [202]. They 
are soluble in a wide variety of organic solvents and are particularly suitable for the 
preparation of solid dispersions by the solvent method [202]. PVP is a water-soluble, 
hydrophilic and hygroscopic polymer made from the monomer N-vinylpyrrolidone. 
Besides that, PVP also possessed chemical and biological inertness, low toxicity, high 
media compatibility, cross-linkable flexibility and other unique properties. The 
chemical structures of IDMC and the PVP repeating unit are shown in Figure 3.1. The 
PVP used in this study has a Tg of 177oC. 
 
 
Figure 3.1 Chemical structures of (A) IDMC; (B) PVP repeating unit  
 
3.2 Preparation of Physical Blends 
The physical blends (PB) of different IDMC to PVP ratios (20:80, 60:40 and 
50:50wt./wt.) were prepared in a turbula mixer (Turbula® T2F) at 49rpm for 45 
minutes. All PB was characterized immediately after harvesting the samples from the 
glass vessels at the end of the mixing process (used for co-milling samples and 
controls). 




3.3.1 Co-milling of IDMC with PVP 
Similar physical blends of IDMC to PVP ratios were prepared using turbula mixer and 
co-milled using Fritsch Pulverisette 5 (Fritsch GmbH Pulverisette 5, Idar-Oberstein, 
Germany), a planetary ball mill equipped with stainless steel jar and balls (diameter 
10mm). The mass ratio of ball to sample was kept at 50:1 [203]. The rotation speed 
was set at 350rev/min and a milling duration of 120 minutes. The co-milled IDMC-
PVP (COM IDMC-PVP) powder was characterized immediately after harvesting the 
sample from the milling jars at the end of the milling process. 
 
3.3.2 Cryo-milling to Generate Amorphous Form of IDMC  
Approximately 2g of γ-IDMC was cryo-milled in an oscillatory ball mill (Mixer Mill, 
Cryomill, Retsch GmbH and Co., Germany). The powder sample was placed in a 
50mL volume stainless steel milling jar containing one stainless steel ball with 50mm 
diameter. Milling jars were then sealed and pre-cooled for 5 minutes with liquid 
nitrogen before milling at 20Hz for 150 minutes. Pre-cooling of the milling chambers 
with liquid nitrogen was performed every 2 minutes. The cryo-milled IDMC powder 
was characterized immediately after harvesting the sample from the milling jars at the 
end of the milling process.  
 
3.4 SAS Experimental Set-up and Procedures 
Carbon dioxide 99.95 % (SOXAL) purity was used as an anti-solvent for SAS process. 
Mixtures of IDMC and PVP at various weight ratios of 85:15, 60:40, 50:50 and 20:80 
were prepared by dissolving it into a mix-solvent containing reagent grade of acetone 
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and dichloromethane (Table 3.1). All the various weight ratios of IDMC and PVP have 
similar IDMC concentration of 12mg/mL. The composition of mix-solvent is 80 and 
20 vol.% of acetone and dichloromethane, respectively. All SAS co-precipitations 
processes were conducted at 85bar and 35oC.  
 
Table 3.1 Composition of co-precipitates prepared by SAS process 
Samplea T (oC) P (bar) IDMC:PVP (wt./wt.) Remark 
SAS IDMC 35 85 100:0 A 
SAS IDMC85-PVP15 35 85 85:15 B  
SAS IDMC60-PVP40 35 85 60:40 C 
SAS IDMC50-PVP50 35 85 50:50 D 
SAS IDMC20-PVP80 35 85 20:80 E 
SAS PVP 35 85 0:100 F 
a All samples were dissolved in a mix- solvents (acetone:dichloromethane=20:80 vol.%). Concentration of IDMC in 
the mixed solvent was 12mg/mL. 
b (A) SAS processed IDMC; (B) SAS IDMC-PVP with 15wt.% of PVP; (C) SAS IDMC-PVP with 40wt.% of PVP; 
(D) SAS IDMC-PVP with 50wt.% of PVP; (E) SAS IDMC-PVP with 80wt.% of PVP; (F) SAS processed PVP 
 
A SAS apparatus (model: SAS50, Thar Technologies Co., USA) was used to generate 
different ratios of SAS IDMC-PVP co-precipitates. Pure IDMC and PVP were also 
generated using SAS process. Figure 3.2 shows the schematic diagram of Thar SAS 
system using Sc-CO2 as anti-solvent. Firstly, the CO2 (1) was cooled down with a bath 
cooler (3) operating at 5oC to assure liquid state in the pump. The liquefied CO2 was 
then pumped into precipitation vessel (10) (500mL vessel, 54mm internal diameter and 
218mm internal height) using a high-pressure pump (11) through the CO2 spray nozzle 
(16) (100μm stainless steel orifice), to fill up the precipitation vessel. The flow-rate of 
CO2 was set at 60g/min. The CO2 was heated using pre-heater (6) before entering the 
precipitation vessel. The pressure (85bar) and temperature (35oC) in precipitation 
vessel was controlled using an automatic back-pressure regulator, ABPR (13) and a 
temperature controller to regulate pre-specified heat to the heating jacket (8), 
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respectively. Once the steady state was established, the solution pump (11) was 
switched on and sprayed the solution of drug and polymer (15) into the precipitation 
vessel through the solution spray nozzle (9) (100μm stainless steel orifice). The flow-
rate of the solution pump was set at 1mL/min and approximately 50-80mL of solution 
of drug and polymer was sprayed into the precipitation vessel. Rapid mixing between 
the two media and the fast diffusion of Sc-CO2 into the drug solvent produces a 
supersaturated solution and causes the drug to precipitate as micronized particles. Once 
sufficient powders were collected in the metal frit (5), the solution pump was switched 
off and Sc-CO2 was continuously pumped into the precipitation vessel to wash-up the 
remaining solvent residual for duration of approximately 60-80 minutes. The 
precipitation vessel was then depressurised gradually to atmospheric pressure using the 
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3.5 Powder Characterizations 
3.5.1 X-ray Powder Diffraction (XRD) 
X-ray diffraction analysis was carried out to evaluate the solid-state chemistry of 
powders. XRD diffractograms were collected for powdered sample using a Bruker 
XRD D8 Advance instrument. Diffraction patterns were measured in-situ by spinning 
sample holders within the X-ray beam. The radiation was generated by Cu filter at 
35kV and 40mA. Data were collected over the 2θ range 4-55o with a step size of 
0.017o and step time of 1s. 
 
3.5.2 Scanning Electron Microscopy (SEM) 
The morphology, particle size and shape of COM IDMC-PVPs and SAS co-
precipitates were characterized using scanning electron microscopy (JEOL JSM-6700F 
SEM-EDX) at 5 kV accelerating voltage. All samples were coated with a thin layer of 
gold using a Cressington Sputter Coater instrument before SEM analyses.  
 
3.5.3 Differential Scanning Calorimetry (DSC) 
DSC thermograms (DSC Q200 V24.4 Build 268, TA Instruments, USA) were obtained 
under a nitrogen gas flow of 50mL/min. Calibration of the DSC instrument was carried 
out using indium as a standard. Sample powders (2–5mg) were crimped in an 
aluminium pan and heated at a rate of 10oC/min from 20 to 200oC. The glass transition 
temperature of generated powders (Tg and melting temperature (Tm) were determined 
using TA Universal Analysis software, version 4.4A. The Tg was determined as the 
midpoint of the change in heat capacity of the sample, while Tm was determined as the 
onset temperatures. 
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3.5.4 USP Dissolution Tester 
The dissolution rates of powdered samples were investigated using a Varian UV-
Visible spectroscopy (model: VK7010, 8-spindle, 8-vessel) USP dissolution 
instrument with automated online UV-Visible measurement. The dissolution medium 
consisted of 900mL of phosphate buffer (pH 6.8) prepared using KH2PO4 and NaOH, 
maintained at temperature of 37±0.5oC and agitation rate was 100rpm.  Each of the 
samples with an amount equivalent to 10.0mg IDMC was used to measure the 
dissolution rate profile. An UV detection wavelength of 320nm was used to determine 
the IDMC concentration. All measurements were carried out in triplicate.  
 
3.5.5 Accelerated Physical Stability Evaluation   
Physical stability stress tests were conducted on powdered samples at controlled 
temperature and relative humidity (RH) based on procedures from International 
Conference on Harmonization ((ICH)–ICH Q1A (R2), Table 2.11). Desiccators with 
storage conditions of 75%RH were prepared using saturated sodium chloride solutions. 
The powdered samples were stored at 75%RH/40oC (temperature controlled oven). 
The changes in samples crystallinity were analyzed using XRD.  
 
3.5.6 Gravimetric Vapour Sorption (GVS) 
The moisture sorption or gravimetric studies were conducted using a humidity-
controlled microbalance (GVS Advantage, Surface Measurement Systems (SMS) Ltd., 
London, UK). The weight change of sample during exposure to a defined condition 
was measured by a sensitive microbalance. The required %RH was controlled by 
mixing dry nitrogen and nitrogen saturated with water vapour, in the corresponding 
proportions, using mass flow controllers. Approximately, 20-50mg of sample was 
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weighed and conducted under 0 to 90%RH in steps of 10%RH for each experiment. 
The system was considered to be in equilibrium if the rate change of mass was less 
than 0.002%/min. All experiments were conducted at 25°C. 
 
3.5.7 Fourier Transformed Infrared Spectroscopy (FTIR) 
FTIR absorbance spectra of different composition of SAS IDMC-PVP co-precipitates, 
COM IDMC-PVPs and PB IDMC-PVPs as well as the untreated IDMC and PVP were 
obtained on a FTIR spectrometer (Perkin–Elmer, 2000, MA, USA). Samples were 
prepared as a pellet in a KBr matrix. Thirty-two scans were collected for each sample 
with a spectral resolution of 4cm-1. 
 
3.5.8 Inverse Gas Chromatography (IGC) 
3.5.8.1  Experimental Apparatus 
In this study, powder surface characterizations were conducted using a commercial 
IGC (Surface Measurement Systems (SMS) Ltd., London, UK) and Table 3.2 shows 
the IGC system design specifications. The IGC system consisted of three separate 
modules built with a SMS mass flow controller module, Hewlett Packard (HP) 6890 
series gas chromatograph (GC) oven and SMS column temperature control oven as 
shown in Figure 3.3 [204]. The IGC is a fully automated system and controlled by 
SMS iGC controller v1.3 software and SMS iGC Analysis Macro is used to analyze 
the data.  The SMS mass flow controller is used to prepare mixtures of dry helium 
carrier gas and the probe vapour. The gas/vapour mixtures are subsequently injected 
into the reference gas (dry helium) and flow through the column packed with sample to 
the detectors. The HP 6890 GC oven is used to control the probe solvents temperature 
and comprising a flame ionization detector (FID) and thermal conductivity detector 
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(TCD) connected in series at the column outlet. The HP 6890 GC data acquisition 
system is used to record data from the FID and TCD. Finally, the SMS column oven is 
used to control the temperature of column packed with samples and operate between 
room temperature to 90oC. Powder is packed into pre-silanized glass columns 
(300×3mm ID) by vertical tapping for 15 minutes and supported with silanized glass 
wool at both end of the glass column. 
 
Table 3.2 SMS IGC system design specifications 
SMS IGC system 
Column temperature 20-90oC 
Humiditya  0-90%RH 
Flow 5-40mL/min (Standard) 
Samplesb 0.1-2.0cm3 
Injections 250μL, 1-95% saturation 





Figure 3.3 SMS IGC schematic diagrams  
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3.5.8.2  Evaluation of Surface Energies of Powders  
Untreated IDMC, PVP, PB, COM and SAS samples were packed vertically into pre-
silanized glass columns and loaded into SMS column oven. Pre-conditioning of 
samples was conducted for 5 hours at 30oC/0%RH. Measurements of the dispersive 
interaction were conducted using 3% of n-decane, n-nonane, n-octane, and n-heptane 
at 30oC. Acetone, ethyl acetate and 2-propanol were used as the polar vapour probes 
(all solvents were HPLC grade). Table 3.3 shows the surface properties of vapour 
probes [205] used in this study. The gas flow rate was set at 10mL/min. All 
measurements were conducted at least with two different columns and 5 
measurements. 
 
Table 3.3 Surface properties of vapour probes used in IGC 
Vapour probes a(𝛾𝛾𝐿𝐿𝑑𝑑 )
1/2  (m²(J/m²)1/2)a Nature 
n-decane 1.15 x 10-19 Non-polar 
n-nonane 1.04 x 10-19 Non-polar 
n-octane 9.19 x 10-20 Non-polar 
n-heptane 8.16 x 10-20 Non-polar 
Acetone 4.37 x 10-20 Polar (Amphoteric) 
Ethyl Acetate 4.62 x 10-20 Polar (Basic) 
2-propanol 6.29 x 10-20 Polar (Acidic) 
a Values were obtained from SMS-iGC analysis software (V.1.3). 
 
The surface properties of samples under investigation are determined from net 
retention volume measurement (VR). For non-polar and polar probes, symmetrical 
peaks were recorded and the retention time was taken as the peak maximum. Under the 
Henry’s Law region, the elution times of vapour probes are independent of the vapour 
probes quantity injected. This region is also called as the infinite dilution range and 
interactions of vapour probe molecules with solid surface occurred predominantly at 
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surface with the highest energy sites. The net retention volume of a vapour probe is 
directly related to its thermodynamic interaction with the sample solid surface, is given 
by: 
𝑉𝑉𝑅𝑅 = 𝑗𝑗𝑑𝑑 ∙ 𝐹𝐹 ∙ (𝑑𝑑𝑅𝑅 − 𝑑𝑑0) ∙ 𝑇𝑇273.15        (3.1) 
 
where T is the column temperature, m is the mass of sample, F is the exit flow-rate, 𝑑𝑑𝑅𝑅  
is the retention time for the adsorbing probe and 𝑑𝑑0 is the mobile phase hold-up time 
(dead time, using methane gas as reference). “j” is the James-Martin correction, which 
corrects the retention time for the pressure drop in the column bed, is given by: 
𝑗𝑗 = 32 ∙ [�𝐺𝐺𝑖𝑖𝐺𝐺0�2−1][�𝐺𝐺𝑖𝑖
𝐺𝐺0�3−1]         (3.2) 
where Pi and P0 are the inlet and outlet column pressures, respectively. 
The molar free energy of adsorption (∆𝐺𝐺𝐴𝐴0) can be determined from IGC infinite probe 
dilution data measurements, is given by: 
−∆𝐺𝐺𝐴𝐴
0 = 𝑅𝑅𝑇𝑇 ∙ 𝑙𝑙𝑙𝑙(𝑉𝑉𝑅𝑅) + 𝐶𝐶        (3.3) 
 
where, R is the ideal gas constant, T is the absolute temperature of the column and C is 
a constant, depending on the reference state of adsorption. In addition ∆𝐺𝐺𝐴𝐴0 is also 
related to the energy of adhesion (WA) between vapour probe molecules and sample 
solid surfaces, is given by: 
−∆𝐺𝐺𝐴𝐴
0 = 𝑁𝑁𝐴𝐴 ∙ 𝑎𝑎 ∙ 𝑊𝑊𝐴𝐴         (3.4) 
 
where NA is Avogadro’s number and “a” is the surface area of the adsorbed probe 
molecule. Based on the Fowkes’s work [206], the WA can be divided into two terms, is 
given by: 
𝑊𝑊𝐴𝐴 = 𝑊𝑊𝐴𝐴𝐴𝐴 + 𝑊𝑊𝐴𝐴𝐺𝐺𝐺𝐺          (3.5) 
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where 𝑊𝑊𝐴𝐴𝐴𝐴 denoting the van der Waals forces and 𝑊𝑊𝐴𝐴𝐺𝐺𝐺𝐺  the specific, mainly polar 
interactions. Hence, the work of adhesion WA as a geometric mean of the dispersive 
surface energy of solid and liquid is given by: 
𝑊𝑊𝐴𝐴 = 2�𝛾𝛾𝑠𝑠𝑑𝑑 ∙ 𝛾𝛾𝐿𝐿𝑑𝑑�12         (3.6) 
 
where 𝛾𝛾𝐺𝐺𝑑𝑑  and 𝛾𝛾𝐿𝐿𝑑𝑑  are the dispersive surface energy of the solid and vapour probe, 
respectively. Equation (3.7) is derived from equations (3.3), (3.4) and (3.6). 
𝑅𝑅𝑇𝑇 ∙ 𝑙𝑙𝑙𝑙 𝑉𝑉𝑅𝑅 = 2 ∙ 𝑎𝑎 ∙ 𝑁𝑁𝐴𝐴 ∙ (𝛾𝛾𝑠𝑠𝑑𝑑)12 ∙ �𝛾𝛾𝐿𝐿𝑑𝑑�12 + B      (3.7) 
 
The dispersive component of a solid 𝛾𝛾𝑠𝑠𝑑𝑑  as described by Schultz et al. [207], can be 
determined by plotting 𝑅𝑅𝑇𝑇 ∙ ln(VR) versus 𝑎𝑎 ∙ �𝛾𝛾𝐿𝐿𝑑𝑑�1/2 as shown in Figure 3.4.  
 
When vapour polar probes are being used, the vertical distance between the polar 
probe data point and the vertical projection to the reference n-alkane line represents the 
specific polar component of the free energy of adsorption (−∆𝐺𝐺𝐺𝐺𝐺𝐺0 ) of a polar probe 
with a solid material as shown in Figure 3.4. In this study, all measurements were 
conducted at infinite dilution range.  
 
Figure 3.4 A typical net retention volume plot versus vapour probe surface properties 
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3.5.8.3  Evaluation of Surface Structural Relaxation 
SAS IDMC60-PVP40 and COM IDMC60-PVP40 samples were packed into silanized 
glass column and were conditioned in the IGC using helium gas as carrier gas 
(20mL/min) at 30oC/0%RH for 12 hours to minimize the effect of water on the surface 
structural relaxation measurements. Once the conditioning cycle was completed, the 
temperature of IGC column oven was increased to 50oC in order to induce surface 
structural relaxation of SAS IDMC60-PVP40 and COM IDMC60-PVP40 samples. In 
this elution study, n-decane (3%) and methane gases were used as probe and reference 
gases, respectively. The n-decane and methane were repeatedly injected sequentially 
into the samples column and the FID responses were recorded. The solvent oven was 
set at 30oC. The estimation of retention volume (𝑉𝑉min ⁡) convergence after aging the 
sample was based on the modified Kohlraush-Williams-Watts (KWW) equation is 
given by: 
𝑉𝑉𝑅𝑅 = 𝑉𝑉𝑑𝑑𝑖𝑖𝑙𝑙 + 𝐴𝐴 ∙ exp �− �tτ�β�       (3.8) 
 
where 𝑉𝑉𝑅𝑅 is a retention volume of n-decane at each time, 𝜏𝜏 is a relaxation time 
constant, 𝛽𝛽 is a relaxation time distribution parameter (0 < 𝛽𝛽 ≤ 1), 𝑑𝑑 is an aging time 
and 𝐴𝐴 is a pre-exponential factor. As (𝐴𝐴 ∙ 𝑒𝑒𝑒𝑒𝑒𝑒�−(𝑑𝑑/𝜏𝜏)𝛽𝛽 �) approached to zero when 𝑑𝑑 
approaches infinite and we can define 𝑉𝑉𝑑𝑑𝑖𝑖𝑙𝑙  as the convergent retention volume. The 𝑉𝑉𝑅𝑅 
data were fitted using MATLAB (version R2010A) to determine the 𝑉𝑉𝑑𝑑𝑖𝑖𝑙𝑙 , 𝜏𝜏 and 𝛽𝛽 
parameters. 
 
3.5.9 Raman Microscopy Mapping (RM)  
Raman mapping (RM) measurements on COM and SAS samples (IDMC:PVP=60:40) 
were performed using a Raman microscope (InVia Reflex, Renishaw, UK) equipped 
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with near infrared enhanced deep-depleted thermoelectrically Peltier cooled CCD array 
detector (576×384 pixels) and a high grade Leica microscope. The sample was 
irradiated with a 785nm near infrared diode laser and a 50× objective lens (N.A.=0.5) 
was used to collect the back-scattered light. Raman point-by-point mapping with a step 
size of 5µm in both the x and y axis directions was performed in an area of 100µm by 
100µm. For each mapping measurements, 441 Raman spectra were collected. 
Measurement scans were collected using a static 1,800 groove per mm dispersive 
grating for the spectral window from 300 to 1,800cm-1. Spectra pre-processing, i.e. de-
spiking was performed in order to remove the spikes due to the presence of cosmic 
rays before the collected data was further analyzed using the band-target entropy 
minimization (BTEM) algorithm [208]. BTEM algorithm is one of the self-modelling 
curve resolution (SMCR) techniques, which can be used to recover the pure 
component spectra of underlying constituents from a set of mixture spectra without 
recourse to any a priori known spectral libraries. 
 
3.5.10 Thermogravimetric (TGA) 
Thermogravimetric (TA instrument, TGA-Q500) analysis was conducted with an 
automatic analyzer system to determine the thermal stability and the composition of 
samples. The weight change of substances was measured in the temperature range 25-
900°C at heating rate of 10°C/min, under nitrogen purge. The nitrogen flow-rate was 
40mL/min. 
 
3.5.11 Gas Chromatography (GC) 
A GC was used to determine the concentration of residual solvents (acetone and 
dichloromethane) in all SAS processed samples, as it is capable to give high-resolution 
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peak, accurate and sensitive detection in low concentration. An Agilent Technologies 
Auto-system (Model 6890N) GC equipped with flame ionization detector (FID) and 
auto-sampler was employed. The capillary column used for GC analysis was a HP-1 
(Agilent column) having dimensions of 30m×0.53mm×2.65µm (L×ID×Film). Helium 
is used as the carrier gas, having a flow-rate of 50cm/s and the split ratio was set at 2:1. 
The detector and injection temperature were set at 300 and 250oC, respectively. The 
temperature profile of the oven is shown in Figure 3.5. The measurement of these 
residual solvents was conducted using an external standard method. This method was 
performed graphically and included in the software data system. The standard 
solutions were prepared by dissolving weighted amounts of residual solvents in GC 
grade dimethyl sulfoxide (DMSO). The injection volume for each run was set at 2µL. 
The residual solvents were analyzed based on the retention times and peak areas on the 
chromatogram. All measurements were carried out in triplicate. 
 
 
Figure 3.5 Temperature profiles for GC oven 
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4. Results and Discussion 
4.1 Solid-State (XRD) 
Figure 4.1 and Figure 4.2 show the X-ray diffractograms of γ-IDMC and α-IDMC 
from the Cambridge Structural Database System (CSD), respectively. Figure 4.3A 
shows the X-ray diffraction pattern of untreated IDMC, which was taken at room 
temperature and used as a reference. The sharp and highly intense Bragg’s peaks 
represented crystalline nature of the drug. The untreated IDMC (crystalline) was in γ-
polymorph form and corresponded to X-ray diffraction characteristic peaks at 2θ 
diffraction angles of 11.6, 16.7 19.6, 21.9, and 26.7o [200]. Figure 4.3G shows the 
untreated PVP composed of a halo diffraction pattern which indicates that the 
untreated PVP was in X-ray amorphous form. 
 
The SAS processed IDMC (crystalline) was in α-polymorph form and retaining the X-
ray diffraction characteristic peaks at 2θ diffraction angles of 8.4, 14.4, 18.5 and 22.1o 
[200] as shown in Figure 4.3B. Recently, Varughese et al. [209] also employed SAS 
process to prepare micronized IDMC particles using acetone and dichloromethane as 
drug solvent. Similarly, they obtained α-polymorph IDMC particles after processing 
the γ-IDMC using SAS. Figure 4.3C, D, E and F show the co-precipitates of IDMC 
with PVP using SAS process. It was noted that the generated SAS IDMC85-PVP15 
co-precipitate (SAS IDMC85-PVP15 denotes SAS co-precipitates of IDMC with 
15wt.% of PVP) was in crystalline form and existed as α-polymorph form powders. As 
the polymer to drug ratios were increased from 40 to 80wt.%,, the generated SAS co-
precipitates were all in X-ray amorphous form. The formation of amorphous forms was 
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verified by XRD analyses, in which the diffraction patterns only showed a halo with 
no crystalline peaks (Figure 4.3D, E and F).  
 
 
Figure 4.1 CSD of γ-IDMC 
 
 
Figure 4.2 CSD of α-IDMC 
γ-IDMC 
α-IDMC 




Figure 4.3 XRDs showing the effect of SAS co-precipitation ratios on crystallinity 
 
Gong et al. [56] also obtained X-ray amorphous IDMC-PVP co-precipitates using 
GAS processing technique. However, the amorphous co-precipitate in Gong’s work 
required much higher PVP content of 80wt.% and above. Kluge et al. [52] studied the 
effect of phenytoin to PVP ratios using precipitation with compressed anti-solvent 
(PCA) process and generated X-ray amorphous co-formulations at PVP contents of 
60wt.% and above. Besides that, these amorphous co-formulations remained stable 
after one year of storage at ambient conditions. Banchero et al. [53] also successfully 
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impregnated piroxicam and PVP using supercritical solvent impregnation process and 
X-ray amorphous impregnated samples were obtained at PVP contents of 85wt.% and 
above. They also reported that polymer molecular weight was mainly found to affect 
the dissolution rate of the different formulations. Similarly, Sethia et al. [55] reported 
that high molecular size of polymers favours the formation of solids solutions and 
could inhibit the re-crystallization of the drug. In comparison to these works, our study 
showed SAS could also generate X-ray amorphous solid dispersions of IDMC and 
even at PVP contents as low as 40wt.%. Besides that, it can alter the polymorphic form 
of γ-IDMC crystalline to the meta-stable α-IDMC form 
 
Cryo-milling and co-milling of γ-IDMC were conducted to generate amorphous form 
of IDMC. Figure 4.4B shows the diffraction pattern of freshly cryo-milled IDMC has a 
halo pattern with no crystalline peaks, which indicates that it was in X-ray amorphous 
form. Similarly, all the different freshly co-milled IDMC-PVP ratios were in X-ray 
amorphous as shown in Figure 4.4C, D and E. The results are similar to those obtained 
by Gupta et al. [128], who have demonstrated using ball-milling to amorphize three 
acidic drugs (naproxen, ketoprofen and indomethacin) and a basic drugs (progesterone) 
when co-milled with neusulin US2 (a synthetic magnesium aluminometasilicate) 
Moreover, co-milling of IDMC with polymers or silica nano-particles to generate 
amorphous solid dispersions have also been reported [13, 128]. Similar to SAS co-
precipitation, it was feasible to generate X-ray amorphous IDMC-PVP co-precipitates 
with PVP contents of 40wt.% and above using co-milling. 




Figure 4.4 XRDs showing the effect of COM co-precipitation ratios on crystallinity 
 
4.2 Morphology (SEM) 
Figure 4.5A, B, C and D shows some of the images of freshly generated SAS IDMC, 
SAS IDMC50-PVP50, SAS IDMC20-PVP80 and COM IDMC50-PVP50, respectively 
(SAS IDMC50-PVP50 denotes SAS co-precipitates of IDMC with 50% of PVP; SAS 
IDMC60-PVP40 denotes SAS co-precipitates with 40wt.% of PVP; COM IDMC50-
PVP50 denotes co-milled IDMC with 50wt.% of PVP). The untreated IDMC has 
multi-faceted structures with diameter of approximately 90µm as shown in Figure 
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4.6A.  SAS IDMC was predominantly thread-like structures as shown in Figure 4.6B. 
Co-precipitates of SAS IDMC60-PVP40, SAS IDMC50-PVP50 and SAS IDMC20-
PVP80 were predominantly agglomerated rounded fines as shown in Figure 4.6C, E 
and G, respectively. All the SAS co-precipitates having approximately 100µm mean 
diameter. 
 
Co-milled powders of COM IDMC60-PVP40, COM IDMC50-PVP50 and COM 
IDMC20-PVP80 were predominantly multi-faceted block structures with rough 
surfaces (probably due to fusion of IDMC and PVP particles) and resembled the 
untreated IDMC’s structure as shown in Figure 4.6D, F and H, respectively. All the co-
milled powders have approximately 80µm mean diameter. Figure 4.6I and J shows 
SAS PVP was predominantly agglomerated rounded fines and the untreated PVP was 
rod-like structures, respectively. Therefore, it was demonstrated that by varying the 
IDMC to PVP weight ratios, the morphologies of untreated IDMC and PVP can be 
modified using the SAS process.  
 
 
Figure 4.5 Images of freshly processed SAS and COM samples 
(A) SAS IDMC; (B) SAS IDMC-PVP co-precipitates with 50 wt% of PVP; (C) SAS IDMC-PVP co-precipitates 
with 80 wt% of PVP; (D) COM IDMC-PVP with 50 wt.% of PVP in the presence of milling balls  
 




Figure 4.6 SEM images of SAS and COM processed samples 
(A) Untreated IDMC; (B) SAS IDMC; (C) SAS IDMC-PVP co-precipitates with 40wt.% of PVP; (D) COM IDMC-
PVP with 40wt.% of PVP; (E) SAS IDMC-PVP co-precipitates with 50wt.% of PVP; (F) COM IDMC-PVP with 
50wt.% of PVP; (G) SAS IDMC-PVP co-precipitates with 80wt.% of PVP; (H) COM IDMC-PVP with 80wt.% of 
PVP; (I) SAS PVP; (J) Untreated PVP   
 
4.3 Glass Transition Temperature of Co-precipitates (DSC) 
DSC analysis shows the onset melting point and enthalpy of fusion of γ–IDMC were 
162oC and 110J/g, respectively (similar to reported value). Figure 4.7 shows the effect 
of PVP ratios on Tg of COM and SAS IDMC-PVP co-precipitates, respectively. The Tg 
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of amorphous IDMC and PVP obtained in this study were 45 and 183oC, respectively. 
Takahiro and Zografi [106] generated amorphous IDMC using solvent evaporation 
method and reported that the Tg of amorphous IDMC was 42oC, which was similar to 
our studies (Figure 4.8). A single Tg between the Tg of the pure components were 
observed for all the different COM and SAS IDMC-PVPs compositions (Figure 4.7) 
and suggested that a single miscible amorphous generated for all COM and SAS 
IMDC co-precipitates. 
 
The Gordon-Taylor (GT) equation [210] was employed to calculate the theoretical Tg 
of the IDMC-PVP blends and to evaluate the extent of COM and SAS co-precipitates 
deviation from ideal mixing by comparing the experimental Tg values with those 
calculated using GT Equation (4.1) .  
 
𝑇𝑇𝑔𝑔 = 𝑤𝑤1𝑇𝑇𝑔𝑔1+𝐾𝐾𝑤𝑤2𝑇𝑇𝑔𝑔2𝑤𝑤1+𝐾𝐾𝑤𝑤2         (4.1) 
 
The w1 and w2 are the weight-fractions of each component, and Tg1 and Tg2 are the 
corresponding Tg values of each component. Using the free volume theory, the 
constant K can be estimated by the density (ρ1 and ρ2) of both components using the 




𝜌𝜌2𝑇𝑇𝑔𝑔2          (4.2) 
 
Figure 4.7 shows the experimental values and theoretical values were in good 
agreement, which indicates a fairly ideal mixing between IDMC and PVP (a similarity 
between IDMC-PVP interactions and IDMC-IDMC interactions). It also shows that 
the Tg of both COM and SAS co-precipitates increased with the concentration of PVP.  




Figure 4.7 Tg of COM and SAS co-precipitates 
 
 
Figure 4.8 DSC thermogram of amorphous IDMC 
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4.4 Dissolution Rate Evaluation 
All the samples used for dissolution rate tests have approximately similar mean 
diameter except SAS IDMC, which has the smallest mean diameter as shown in the 
SEM images in Figure 4.6. Figure 4.9 show the SAS IDMC (crystalline form) has a 
higher dissolution rate as compared to the untreated IDMC (crystalline form). The 
enhancement of IDMC dissolution rate using SAS IDMC sample was mainly due to 
the increase of surface area and the IDMC meta-stable α-polymorph form [212]. The 
dissolution rate of IDMC was significantly enhanced in amorphous SAS co-
precipitates as shown in Figure 4.9. Gong et al. [56] reported that the dissolution rate 
of IDMC-PVP co-formulations using solvent-free supercritical process enhanced the 
dissolution of IDMC at low concentration but an increase in PVP content could retard 
the dissolution rate of IDMC. Mauro et al. [57] also reported similar results using 
supercritical solvent impregnation of piroxicam on PVP at various polymer molecular 
weights. Recently, Uzun et al. [163], reported that the release rate of SAS cefuroxime 
acetil-PVP co-precipitates (1:1w/w) was almost 10 times slower than the untreated 
drug. They also found that as the ratio of PVP increased the cefuroxime acetil release 
rate also increased due to the wetting effect of PVP.  
 
Figure 4.10 shows the dissolution rate of amorphous COM IDMC-PVPs have 
significantly enhanced the dissolution rate as compared to untreated IDMC. The COM 
IDMC-PVPs also have almost similar dissolution rate as the SAS IDMC-PVP co-
precipitates. The enhanced dissolution rates of IDMC are likely due to the amorphous 
nature of COM IDMC-PVPs and SAS co-precipitates, increase in surface areas or 
both. Lee et al. [213] has also demonstrated co-milling of felodipine with HPMC and 
poloxamer improved the dissolution rate of felodipine as compared to the untreated 
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drug because of the solubilization effect of polymer and milling (increase in particle 
surface area). Mura et al. [129] reported that amorphous form of the milled glisentide 
was the main factor for obtaining 100% dissolution efficiency as compared to the 
untreated drug. They also found that further significant improvement in dissolution 
rate of glisentide was directly related to the polymer content in the mixture obtained by 
co-milled with PVP. Figure 4.11 shows all physical blends of PB IDMC-PVP did not 
show improved dissolution rates as compared to untreated IDMC, which indicate that 
physical mixing with PVP has no influence on the dissolution rate of IDMC. 
Therefore, our studies also revealed that the dissolution rate of IDMC was significantly 
enhanced using amorphous form of COM and SAS co-precipitates and was 
independent on the polymer ratio when both COM and SAS-co-precipitates were in 
fully X-ray amorphous state.  
 
 
Figure 4.9 Dissolution of SAS processed samples versus untreated IDMC 
 




Figure 4.10 Dissolution of COM IDMC-PVPs versus untreated IDMC 
 
Figure 4.11 Dissolution of physical blended versus untreated IDMC  
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4.5 Accelerated Physical Stability Evaluation 
The physical stability of cryo-milled IDMC, SAS co-precipitates and COM IDMC-
PVPs was evaluated under accelerated stress conditions (75RH%/40oC) based on the 
International Conference on Harmonization (ICH)–ICH Q1A (R2) for more than 6 
months. Figure 4.12 shows the amorphous form of cryo-milled IDMC was physically 
unstable and re-crystallized to γ-IDMC after 1 day of storage at 75RH%/40oC. The 
diffractograms in Figure 4.13 shows the SAS co-precipitates with PVP content more 
than 40wt.% remained as stable X-ray amorphous after more than 6 months of storage, 
indicating that no re-crystallization of IDMC in the PVP matrix. Recently, it was 
similarly reported that the physical stability of the paclitaxel-hydroxypropyl-β-
cyclodextrin-polyoxyl 40 hydrogenated caster oil (1:20:40 weight ratio) solid 
dispersions prepared by SAS remained stable after 6 months of storage at 
75RH%/40oC [214]. 
 
Figure 4.12 XRDs of cryo-milled IDMC before/after storage at 75%RH/40oC 
 




Figure 4.13 XRDs of SAS co-precipitates before/after storage at 75%RH/40oC 
 
A comparison between co-milled and SAS processed IDMC-PVP was shown in Figure 
4.14 and Figure 4.13, respectively. The diffractograms in Figure 4.14 show all the 
COM IDMC-PVPs re-crystallized from amorphous IDMC to γ-IDMC after stored at 
75RH%/40oC and the re-crystallization was first observed at COM IDMC-PVP with 
the least PVP content (40wt.%). In the order of ascending rate of re-crystallization, 
COM IDMC60-PVP40, COM IDMC50-PVP50 and COM IDMC20-PVP80 re-
crystallized after stored for 7, 50 and 109 days at 75RH%/40oC, respectively. It was 
reported that the re-crystallization of amorphous IDMC is temperature dependent and 
temperatures below Tg (43-45oC) favour the formation of γ-polymorph [30, 215], 
which were similarly observed in our results. 
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Chieng et al. [130] performed physical characterization and stability of amorphous 
IDMC and hydrochloride binary systems prepared by co-milling. It was found that 
amorphous binary system with mass ratio 1:1 was stable after 30 days of storage under 
dry conditions (silica gels) at 4 and 25oC. They reported that this amorphous binary 
system has potential to be developed as dosage form of IDMC with a higher 
dissolution rate. On another hand, no re-crystallization were observed in all SAS co-
precipitates after storage more than 6 months under same conditions, indicating SAS 
co-precipitates are more physically stable than COM IDMC-PVPs. It was believed that 
the re-crystallization of COM IDMC-PVPs could be due to the presence of crystalline 
phase which promotes and accelerates the re-crystallization of amorphous form of 
COM IDMC-PVP. This was further supported in our Raman mapping studies (see 
Chapter 4.10), where γ-IDMC crystal seeds were found present in COM samples. Paes 
et al. [211] reported that the re-crystallization of form I cellulose generated using ball-
milling was due to the presence of small amount of residual form I cellulose (probably 
less than 5%) acting as a template for the crystallizing material. Besides that, 
Shakhtshneider et al. [126] also reported that the amorphous state of IDMC generated 
using cryo-milling with polymer is less stable than solvent evaporation technique 
could be attributed by the presence of IDMC crystal seeds. 
 





Figure 4.14 XRDs of COM IDMC-PVPs before/after storage at 75%RH/40oC 
 
 
Generally, the physical stability of amorphous drug prepared by milling of crystalline 
solids is less stable as compared to that obtained by quenching of liquid. Fukuoka et al. 
[216] reported that glassy state of IDMC generated by very slow cooling of the liquid 
is stable against crystallization for 2 years, but amorphous state of IDMC generated by 
milling is less stable and re-crystallized to 90% after approximately 13-15 hours [30]. 
The presence of PVP in SAS co-precipitates and co-milled IDMC-PVP could have 
inhibited the re-crystallization of IDMC by restricting the mobility of IDMC molecules 
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and presence of molecular-interaction (hydrogen bonding) between IDMC and PVP 
molecules. Therefore, in the later study, the amorphous forms of COM IDMC60-
PVP40 and SAS IDMC60-PVP40 were selected to investigate the surface properties 
and nature/structural relaxation because of its higher tendency to structural relaxation, 
which can be induced using n-decane (vapour probe) in IGC experiments. 
 
4.6 Moisture Sorption Isotherm (GVS) 
The moisture sorption behaviour of cryo-milled IDMC, COM, SAS and PB IDMC-
PVPs were investigated using step adsorption (10 to 90%RH). As expected, no 
significant moisture uptake was observed for untreated crystalline IDMC (hydrophobic 
API in nature) as shown in Figure 4.15. The moisture sorption uptake of “IDMC-
milled-5min” (ball milling of IDMC for 5 minutes) increased as compared to untreated 
IDMC, which could be due to the milling-induced disorder and defect on the surface of 
the IDMC particles (probably generation of some amorphous surface) although its 
XRD shows it was mainly still in crystalline form (inset of Figure 4.15C). This 
difference was not surprising because XRD is more sensitive in detecting crystallinity 
(detection limit, 1-10% of amorphous [217, 218]) and GVS is more sensitive in 
detecting amorphous content (detection limit, 0.5% of amorphous [217, 219]).  
 
The moisture sorption uptake of amorphous form IDMC generated using cryo-milling 
was significant higher than its crystalline form and re-crystallization was onset at 
50%RH (characterized by a sudden weight loss as shown in Figure 4.15 and Figure 
4.16). The characteristic of moisture adsorption-release behaviour of amorphous 
samples at certain %RH due to the moisture-induced re-crystallization is well-
documented [220, 221]. The re-crystallization of amorphous IDMC to 𝛾𝛾-IDMC was 
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further evidence by XRD (measured immediately after GVS experimental) with the 
presence of crystalline peaks as shown in inset of Figure 4.15A). 
 
 








Figure 4.16 GVS mass-plot of amorphous cryo-milled IDMC 
 
 
The effect of IDMC-PVP ratios in COM and SAS co-precipitates on moisture sorption 
was also studied. As indicated in Figure 4.17 and Figure 4.18 the moisture sorption 
uptake of COM and SAS co-precipitates increases with PVP contents, respectively. 
The moisture sorption profiles of both amorphous forms of COM and SAS co-
precipitates were almost similar and also observed that there were no moisture-induced 
re-crystallization across the entire experimental %RH. XRD were also performed 
immediately after GVS experimental on all the amorphous forms COM and SAS co-
precipitates and the diffraction patterns showed a halo with no crystalline peaks 
indicating no re-crystallization occurred throughout the GVS experimental. Examples 
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of GVS mass plot of COM and SAS co-precipitates (IDMC:PVP=60:40) were shown 
in Figure 4.20 and Figure 4.21, respectively. Balani et al. [14] investigated the 
moisture sorption profiles of co-milled salbutamol sulphate-PVP at different PVP 
ratios. They reported that moisture sorption of co-milled salbutamol sulphate-PVP 
increased with PVP ratios and observed the moisture sorption profile has an inflexion 
(some extent of re-crystallization) between 50-70%RH for co-milled salbutamol 
sulphate-PVP with PVP content less than 33%wt./wt. Besides that, no deliquescence of 
samples were observed on all the COM and SAS co-precipitates and Figure 4.23 
shows the GVS-microscopy images of COM and SAS IDMC60-PVP40 co-precipitates 
at 0 and 90%RH/25oC. However, it was also noted that the proportions of moisture 
sorption uptake of COM and SAS co-precipitates were not similar to its corresponding 
PB IDMC-PVPs (Figure 4.19). Apparently, the PVP becoming less hygroscopic when 
more IDMC is incorporated into the COM and SAS co-precipitates. The reduced 
moisture sorption uptake can be considered as hydrophobization of PVP and could be 
due to the additional physical-chemical effects (such as changes in surface energetics 
and/or molecular interactions existed between IDMC and PVP). Hydrophobization 
phenomena of PVP solid dispersions containing hydrophobic drugs which caused non-
proportional moisture sorption uptake have been reported [222, 223]. They reported 
that moisture sorption uptake deviations of solid dispersion could be related to the 
interactions between carrier and incorporated drug molecule. Shaun et al. [224] also 
investigated the effect of moisture on PVP in accelerated stability test. They reported 
that the moisture sorption isotherm of PVP shows absorption of a significant quantity 
of water on exposure to elevated humidity.  
 




Figure 4.17 Moisture vapour sorption isotherm of COM IDMC-PVPs samples 
 
 
Figure 4.18 Moisture vapour sorption isotherm of SAS IDMC-PVPs samples 








Figure 4.20 GVS mass-plot of COM IDMC60-PVP40 
 








Figure 4.22 GVS mass-plot of PB IDMC60-PVP40 
 




Figure 4.23 GVS-microscopy images of COM and SAS IDMC60-PVP40  
 
4.7 Drug-Polymer Interactions (FTIR) 
FTIR studies were conducted to further investigate the nature and extent of interactions 
between drug and polymeric carrier in the solid state. In polymer blends, mixing of 
two components at the molecular level will cause changes in the oscillating dipole of 
the molecules. This will manifest itself as changes in the frequency and bandwidth of 
interacting groups in the spectrum. Therefore, if interaction existed between the drug 
and polymer, the functional groups in the FTIR spectra will show band shifts and 
broadening as compared to the spectra of the pure drug and polymer [225]. Figure 4.24 
shows the untreated IDMC infrared (IR) spectra was a γ polymorph as reported in the 
literature [30]. The IR spectra (Figure 4.24) showed the presence of two strong bands 
at 1,717 and 1,692cm-1 which corresponded to asymmetric acid C=O of a cyclic dimer 
and benzoyl C=O, respectively (Figure 2.2A). As for untreated PVP, the strong 
bandwidth at 1,675cm-1 was corresponded to the non-hydrogen bonded amide C=O 
(Figure 2.2B). At 40wt.% of PVP and above, both of the COM IDMC-PVPs and SAS 
No deliquescence of samples was observed  
No deliquescence of samples was observed  
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co-precipitates have a single broad peak at 1,724cm-1 which developed into a shoulder 
as the concentration of PVP increases and the absorbance of PVP carbonyl dominates 
the spectrum. The peak at 1,724cm-1 is assigned to the non hydrogen bonded carbonyl 
stretch of an acid group of an IDMC molecule which is hydrogen bonded through the 
hydroxyl group to a PVP molecule [30] (Figure 4.26B). This phenomenon was not 
present in the physical blends of IDMC-PVPs IR spectra, which indicates no hydrogen 
bonding between IDMC and PVP molecules (Figure 4.25).  
 
Figure 4.24 IR spectra of COM IDMC-PVPs and SAS co-precipitates 
 




Figure 4.25 IR spectra of physical blended of IDMC-PVPs 
 
 
Figure 4.26 (A) Dimerization of γ-IDMC; (B) Hydrogen bonding between IDMC-PVP 
 
The IDMC molecules existed as symmetrical dimers (Figure 4.26A), where two IDMC 
molecules are associated through intermolecular hydrogen bonding between their 
carboxylic acid functional groups [30]. During the co-milling and SAS process, the 
IDMC dimers may have been disrupted in the presence of PVP and lead to the 
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hydroxyl group of carboxylic acid functional group in IDMC to form intermolecular 
hydrogen bonding with PVP and increased its bond strength. The ability to inhibit 
dimerization would seem to be important because such dimerization is required in the 
formation of the γ–crystal nucleus, as shown from its crystal structure [226] and thus 
prevents molecules from making contact with each other. As a result of such obstacle, 
the desired atomic and molecular arrangements for forming a crystal lattice were 
inhibited (through IDMC-PVP hydrogen bonding) and thus preventing re-
crystallization.  
 
It is known that hydrogen bonding plays a crucial role in the stabilization of organic 
structures [227]. There are many different configuration or ways hydrogen bonds can 
be formed between different acceptors and donors and caused the retarded re-
crystallization of molecules due to the possibility of mismatches in hydrogen bonds 
[228, 229]. Price [230] proposed an interaction model to explain the formation of a 
non-crystalline state by the disruption of specific drug-drug interactions or by the 
formation of specific drug-excipient interactions. He reported that the re-crystallization 
of glasses network is prevented by directional bonds that inhibit the formation of long 
range order. Kim and Karis [231] also proposed that hydrogen bonds act as a network 
to prevent re-crystallization of sugar glasses.  
 
Therefore, in our study the presence of PVP in the amorphous phase of COM IDMC-
PVPs and SAS co-precipitates could be stabilized by the intermolecular hydrogen 
bond between IDMC and PVP and improved its physical stability against re-
crystallization.  Besides that, the PVP hydrophobization phenomena shown in GVS 
moisture sorption experimental was supported by IR spectra of COM IDMC-PVPs and 
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SAS co-precipitates with the presence of intermolecular interactions between IDMC 
and PVP molecules. 
 
4.8 Surface Energy Properties (IGC) 
4.8.1 Dispersive Energy 
The dispersive energies (𝛾𝛾𝐺𝐺𝑑𝑑) of samples were determined from the IGC retention 
volume of n-alkane hydrocarbon series (C7-C10). Ball milling of IDMC for 5 minutes 
was also conducted as a comparison and denoted as IDMC-milled-5min. Table 4.1 
shows the 𝛾𝛾𝐺𝐺𝑑𝑑  of IDMC-milled-5min, amorphous (cryo-milled IDMC) and unmilled 
crystalline IDMC. In ascending order of dispersive energy, the IDMC-milled-5min 
(52.0mJ/m2) has the highest dispersive energy followed by unmilled IDMC 
(50.1mJ/m2) and amorphous IDMC (cryo-milled) (47.4mJ/m2). The value 𝛾𝛾𝐺𝐺𝑑𝑑  of 
IDMC-milled-5min (XRD shows mainly crystalline, inset Figure 4.15C) was higher 
than its crystalline form could be due to the crystal fracturing and reducing in particle 
size during milling. Heng et al. [232] reported that 𝛾𝛾𝐺𝐺𝑑𝑑  of milled paracetamol to be 
inversely related to the particle size. On the other hand, York et al. [233] reported that 
as particle size of D, L-propranolol hydrochloride decreases during milling, the value 
of  𝛾𝛾𝐺𝐺𝑑𝑑  increases until a critical point is reached where there is a plateau followed by a 
small decrease for the finest powder. However, it was also noted that the amorphous 
form of IDMC generated using cryo-milling has the lowest value of 𝛾𝛾𝐺𝐺𝑑𝑑 . This 
phenomenon was also observed by Hadjar et al. [234, 235] where the value of the 
dispersive component of the surface energy of the crystalline silica was higher than 
that of the amorphous silica. 
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𝑑𝑑  (mJ/m2) 50.1 (±1.5) 52.0 (±0.4) 47.4 (±0.3) 
 
Table 4.2 Dispersive energy of COM and SAS IDMC60-PVP40 co-precipitates 



















38.5 (±1.5) 47.8 (±0.2) 53.2 (±0.3) 45.4 (±2.3) 42.3 (±1.9) 
 
Table 4.2 shows the dispersive energies of PB IDMC60-PVP40 (as a control), COM 
IDMC60-PVP40 and SAS IDMC60-PVP40. As a comparison, ball-milling of COM 
IDMC60-PVP40 for 5 minutes was also conducted and denoted as “COM-5min”. 
Similarly, it was noted that 𝛾𝛾𝐺𝐺𝑑𝑑  of COM-5min (53.2mJ/m
2) was higher than its physical 
blended mixtures (47.8mJ/m2). Again the same observations were also obtained for 
𝛾𝛾𝐺𝐺
𝑑𝑑of both amorphous forms co-precipitates (SAS IDMC60-PVP40 (42.3mJ/m2) and 
COM IDMC60-PVP40 (45.4mJ/m2)) were lower than 𝛾𝛾𝐺𝐺𝑑𝑑  of PB IDMC60-PVP40 
(47.8mJ/m2). Grimsey et al. [236] compared the surface energetic properties of 
unprocessed poly(l-latide) microparticles (PLLA) with particles generated from spray 
drying and solution enhanced dispersion with supercritical fluids (SEDS) process. The 
SEDS process generated the lowest dispersive energy (34.5mJ/m2) of PLLA, while the 
spray dried amorphous PLLA (35.7mJ/m2) has a lower dispersive energy as compared 
to the unprocessed semi-crystalline PPLA (36.6mJ/m2). They concluded that 
processing methods used to generate PLLA particles has a significant effect on the 
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crystallinity and specific component of the surface free energy of the resulting powder, 
with material prepared by SEDS having significantly lower surface free energy. 
Newell et al. [196] also reported that dispersive energy of spray dried amorphous 
forms of lactose (37.1mJ/m2) was lower as compared to the milled lactose (0.7% 
amorphous) (41.6mJ/m2). They suggested different processing methods could generate 
particles with different orientations and spacing between the surface molecules and 
thus giving rise to the different energy states.   
 
From a thermodynamic standpoint, the crystalline and amorphous forms of IDMC are 
the most and least stable, respectively. A possible explanation to this phenomenon 
could be due to the amorphous nature of material in possessing the highest free energy 
and degree of molecular mobility. Besides that, the disorder in the amorphous material 
is co-operative in nature. Therefore, with the combination of high molecular mobility 
and co-operative of amorphous form has enabled the molecules in the bulk of the 
amorphous phase to re-orientate/re-arrangement in order to minimize the energy of its 
surface. Although not completely the same, this phenomenon is mimic the ability of a 
liquid to minimize its interfacial energy. Recently, Chamarthy et al. [237] reported that 
amorphous forms of both griseofulvin and felodipine generated using melt-quench 
cooling have lower 𝛾𝛾𝐺𝐺𝑑𝑑  than its crystalline forms. On the other hand, crystal 
defects/fractures caused during milling do not exhibit the co-operative re-arrangement 
as of the amorphous form. Therefore, there is no co-operative molecular re-
arrangement to minimize the activated surface energy. In this study, although the 
surface energy of amorphous form was more lower as compared to its crystalline form 
but it still follows the thermodynamic stability where in rank order of stability, 
crystalline > milled (mainly crystalline) > amorphous. Therefore, in this study it was 
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demonstrated that the potential of IGC to detect and quantify differences in surface 
energetic of powder samples before/after micronization as well as the different 
processing methods which is importance for secondary processing such as powder 
flow-ability. 
 
4.8.2 Specific Polar Energy 
The specific polar component free energy of adsorption (−∆𝐺𝐺𝐺𝐺𝐺𝐺0 ) of each different 
vapour polar probes (acetone, ethyl acetate and 2-propanol) was determined from the 
difference between the (RT ∙ ln(VR)) values obtained and the n-alkane reference line 
(dispersive line). Table 4.3 shows the −∆GSP
0  of unmilled crystalline, milled (5mins) 
and amorphous IDMC. Ethyl acetate and 2-propanol were used to probe the acidic and 
basic nature of sample surfaces, respectively. Overall the surfaces of crystalline, 
IDMC-milled-5min and amorphous IDMC were in acidic nature due to the high 
interaction with ethyl acetate and weak interaction with 2-propanol. 
 












Acetone (amphoteric) 6.2 (±0.4) 6.6 (±0.1) 4.2 (±0.1) 
Ethyl Acetate (basic) 8.7 (±0.1) 9.3 (±0.1) 8.5 (±0.1) 





                                                                                                                            Chapter 4 
93 
 























6.2 (±0.4) 7.4 (±0.4) 6.6 (±0.2) 6.3 (±0.1) 6.6 (±0.3) 6.3 (±0.2) 
Ethyl 
Acetate 8.7 (±0.1) 8.0 (±0.3) 8.6 (±0.1) 9.2 (±0.1) 8.0 (±0.2) 7.5 (±0.8) 
2-propanol 4.4 (±0.1) 7.1 (±0.5) 4.4 (±0.1) 4.6 (±0.1) 5.8 (±0.4) 5.9 (±0.1) 
 
Table 4.4 shows the amorphous COM and SAS co-precipitates acidic components of 
surface energy increased, while basic component decreased indicating that the surfaces 
COM and SAS co-precipitates were slight more basics as compared to its physical 
blended mixture (PB). The increased surface basic nature of amorphous COM and 
SAS could be due hydrogen bonding formation between PVP amide carbonyl and 
IDMC carboxylic acid hydroxyl groups. Watanabe et al. [13] investigated the carbon 
chemical states (using 13C-CP/MAS-NMR) of co-milled IDMC-PVP solid dispersion 
and reported that hydrogen bonding formation between the PVP amide carbonyl and 
IDMC carboxylic acid hydroxyl groups. They observed that formation of hydrogen 
bond in the co-milled IDMC-PVP solid dispersion caused a higher chemical shift in 
NMR spectra due to a delocalization of electron. As a result, a decrease in the peak of 
carbonyl group of PVP would indicate hydrogen bond formation between the PVP 
amide carbonyl group at the surface of PVP particles and the carboxyl group of IDMC 
molecules by co-milling. FTIR spectra of COM and SAS IDMC60-PVP40 (Figure 
4.24) from our studies also suggested that hydrogen bonding was formed between PVP 
amide carbonyl and IDMC carboxylic acid hydroxyl groups. In this study, it was 
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demonstrated that IGC technique was practically useful to characterize the surface 
energetic of powdered materials and also provided important relations for 
understanding how the surface of materials change as they are being processed, and 
how these changes affect material behaviour.  
 
4.9 Surface Structural Relaxation (IGC) 
Kawakami and Pikal [238] and Liu et al. [239] reported that structural relaxation might 
be related to the loss of energy during aging. Recently, Hasegawa et al. [64] 
demonstrated that surface energy of an amorphous system decreased during aging 
using IGC. They also reported that decreased of surface energy was related to 
structural relaxation. Therefore, in this study, a similar method applied by Hasegawa et 
al. [64] was used to determine the relaxation profile of COM and SAS IDMC60-
PVP40 co-precipitates using n-decane (C10) as the probe because of its longer retention 
time (higher sensitivity and interaction with solid surface). Three different batches 
were used for the each measurement and Figure 4.27 and Figure 4.28 show one of the 
batches relaxation profiles of COM and SAS IDMC60-PVP40 co-precipitates as a 
function of aging time, respectively. The retention volumes (VR) of both COM and 
SAS IDMC60-PVP40 decreased drastically in the first 10 hours and then decreased at 
a slower rate until it reached plateau. However, there was a slight difference between 
the absolute VR measured for each batch, which may be due to the difference in the 
surface area and/or the morphology. Nonetheless, similar trend of relaxation profiles 
were obtained. As a control, the relaxation profile of unmilled IDMC (crystalline) was 
also measured and no significant decrease in VR was observed as shown in Figure 
4.29. XRD were also conducted on the COM and SAS IDMC60-PVP40 co-
precipitates that were treated with n-decane using IGC. Both samples have diffraction 
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patterns with a halo and no crystalline peaks indicating no re-crystallization occurred 
throughout the IGC aging experiments. Therefore, the changes of VR were due to the 
structural relaxation of amorphous form of both COM and SAS IDMC60-PVP40. 
 
Figure 4.27 Aging time of COM IDMC60-PVP40 versus change of VR (C10) at 50oC 
 
 
Figure 4.28 Aging time of SAS IDMC60-PVP40 versus change of VR (C10) at 50oC 




Figure 4.29 Aging time of unmilled IDMC versus change of VR (C10) at 50oC 
 
 
KWW equation was used to fit the relaxation profile of samples and Table 4.5 shows 
the structural relaxation parameters of COM and SAS IDMC60-PVP40. Kawakami 
and Pikal [238] suggested to employ the use of 𝜏𝜏𝛽𝛽  as an appropriate parameter to 
compare amorphous forms. The 𝜏𝜏𝛽𝛽  of SAS IDMC60-PVP40 (4.4) was higher than 
COM IDMC60-PVP40 (3.6) indicating that surface structural relaxation of COM 
IDMC60-PVP40 was faster than SAS IDMC60-PVP40. Besides that, the 𝛽𝛽 value of 
COM (0.41) was lower than SAS IDMC60-PVP40 (0.55) indicating that the SAS co-
precipitate has a more homogenous distribution of relaxation than COM samples. 
Therefore, in this study it was demonstrated that the amorphous form samples 
generated from different processing methods have different surface structural 
relaxations. This result also supported the XRD showing that SAS co-precipitate was 
more physically stable than COM sample. It also demonstrated that IGC can be used to 
distinguish different amorphous forms processed by SAS and COM methods which 
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were not able to be distinguished by XRD and GVS. Moreover, it can be used to detect 
the structural relaxation at the surface of amorphous samples. 
 
Table 4.5 Surface structural relaxation parameters of COM and SAS IDMC60-PVP40  
Samples 𝜏𝜏(ℎ) 𝛽𝛽 𝜏𝜏𝛽𝛽  
COM IDMC60-PVP40 (Amorphous) 22.7 (± 2.7) 0.41 (± 0.03) 3.6 
SAS IDMC60-PVP40 (Amorphous) 14.7 (± 4.4) 0.55 (± 0.02) 4.4 
 
 
4.10 Raman Mapping (RM) 
The collected Raman mapping data of COM IDMC60-PVP40 sample were pre-
processed and analyzed using the BTEM method. Three spectra were extracted from 
COM sample via BTEM and were compared to the pure component reference spectra 
of PVP, amorphous IDMC, and crystalline γ-IDMC as shown in Figure 4.30. 
 
Figure 4.30 Pure component reference spectra of PVP, amorphous and γ-IDMC 
 
 
Figure 4.31A shows the extracted spectra of three pure components were similar to its 
pure component reference spectra (PVP and both amorphous and crystalline γ-IDMC). 
Furthermore, the spatial distributions of these three components were generated by 
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projecting the extracted pure component spectra onto the measured Raman mapping 
data as shown in Figure 4.31B. The spatial distribution of COM sample shows that 
PVP and amorphous IDMC were almost well distributed on the mapped areas with 
5µm resolution. However, it was also noted that in some mapping area there were 
presence of crystalline γ-IDMC seeds, which may act as the precursor for re-
crystallization of COM samples. Moreover, the γ-IDMC crystalline seeds were not 
well-distributed and only can be found in some random locations. The Raman mapping 
results of COM sample also further supported the characterization results obtained 
from XRD which show COM samples re-crystallized after storage at 40oC/75%RH. 
Although, co-milling of γ-IDMC with PVP has generally improved the physical 
stability of amorphous IDMC, however, the re-crystallization was still likely to happen 
upon storage due to the presence of crystalline γ-IDMC seeds in the COM sample. 
 
Similarly, the collected Raman mapping data of SAS IDMC60-PVP40 sample were 
pre-processed via BTEM method. The BTEM analysis of SAS sample was not able to 
extract its pure components and only resulted in the reconstruction of single 
component spectrum as shown in Figure 4.32A. The extracted spectrum exhibited a 
combination of Raman peaks of PVP and amorphous IDMC, which show a high 
resemblance to Raman peaks of PVP and amorphous IDMC pure component 
references. This result suggested that there was co-linearity composition between PVP 
and amorphous IDMC (having homogeneous distribution of PVP and amorphous 
IDMC component in SAS sample). This was also evidence in the generated spatial 
distribution of SAS sample showing a homogeneous distribution of PVP and 
amorphous IDMC components in the mapped areas with 5µm resolution as shown in 
Figure 4.32B. In addition, no crystalline γ-IDMC seed was observed in SAS sample. 
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Therefore, the Raman mapping and BTEM analysis also supported the results obtained 
from XRD and IGC, which show that SAS sample was physically more stable than 
COM sample. 
 
Figure 4.31 (A) Extracted COM spectra via BTEM; (B) COM spatial distributions  
 
 
Figure 4.32 (A) Extracted SAS spectra via BTEM; (B) SAS spatial distributions   
(A) (B) 
(A)  (B) COM IDMC60-PVP40 
SAS IDMC60-PVP40 
                                                                                                                            Chapter 4 
100 
 
4.11 Drug Content in COM and SAS Co-precipitates (TGA) 
Figure 4.33A and E shows the untreated PVP and SAS IDMC started to decompose at 
approximately 380oC and 220oC (which is similar to the reported value [200]), 
respectively. The thermograms also show the composition of both co-milled powders 
(COM IDMC60-PVP40, COM IDMC50-PVP50 and COM IDMC20-PVP80) and SAS 
co-precipitates (SAS IDMC60-PVP40, SAS IDMC50-PVP50 and SAS IDMC20-
PVP80) were similar to the experimental feed composition, which indicate that the co-
milling and SAS co-precipitating process were well controlled. As a control, respective 
physical blends of PB IDMC-PVPs were also analyzed (Figure 4.34) and their 
thermograms also superimposed on COM IDMC-PVPs and SAS co-precipitates, 
which provide further evidence that COM IDMC-PVPs and SAS co-precipitates have 
similar compositions to the experimental feed compositions.  
 








Figure 4.34 Thermograms of SAS co-precipitates and PB (IDMC:PVP=50:50) 
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4.12 Residual Solvents in SAS Processed Samples (GC) 
Based on the ICH Q3C (R4) guideline for residual solvents content in pharmaceutical 
products, dichloromethane (DCM) and acetone (AC) are classified as Class II and 
Class III solvents, respectively. The objective of this guideline is to recommend 
acceptable amounts of residual solvents in pharmaceuticals for the safety of the patient. 
According to the guideline, Class II solvents are associated with less severe toxicity 
and should be limited in order to protect patients from potential adverse effects. The 
concentration limit for DCM in pharmaceutical products is 600 ppm. Class III covers 
less toxic solvents, which are of lower risk to human health. The concentration limit 
for AC is less than 5,000 ppm. GC-FID was used to measure the residual solvents 
content in SAS processed samples. Figure 4.35 shows the calibration curves obtained 
from GC analysis of acetone and dichloromethane. Table 4.6 shows the content of 
residual solvents in SAS processed samples. The results show that AC was not 
detectable in all SAS processed samples. Besides that, the concentrations of DCM 
were less than 50 ppm in all the SAS processed samples, which is way below the ICH 
acceptable limit. Similarly, Bleich and Mueller [166] employed SCF anti-solvent 
process to generate drug loaded particles (IDMC-PLA) and the DCM residual solvents 
in the co-precipitates were less than 30 ppm. Therefore, SAS process could be a useful 
method for preparing drug delivery systems with low content of residual solvents. 
Moreover, the SAS washing process step (after particle formation) is very efficient in 
extracting residual solvents [166].  
 








Table 4.6 Residual solvents content in SAS processed samples 
Sample Acetone content (ppm) Dichloromethane content (ppm) 
SAS IDMC ND 50 
SAS IDMC85-PVP15 ND 48 
SAS IDMC60-PVP40 ND 46 
SAS IDMC50-PVP50 ND 44 
SAS IDMC20-PVP80 ND 45 
SAS PVP ND 48 
ND: Not detectable (Detection limit is 5 ppm) 
 
 




Our results revealed that it is technically feasible to generate X-ray amorphous IDMC-
PVP with minimum of 40wt.% PVP using co-milling and SAS co-precipitation. The 
morphology of the SAS co-precipitates can be modified by varying the drug to 
polymer ratio but not using co-milling. Amorphous forms of IDMC produced by COM 
and SAS have significantly improved the dissolution as compared to the crystalline 
form and its physical blends, respectively. 
 
Amorphous pure form of IDMC generated using cryo-milling was physically unstable 
and re-crystallized to γ-IDMC after one day of storage at 75%RH/40oC. The use of 
crystallization inhibitors such as PVP to generate a single-phase amorphous mixture 
with PVP using co-milling and SAS co-precipitation have improved the physical 
stability of the amorphous form of IDMC. However, COM IDMC-PVP samples with 
PVP contents less than 50wt.%  re-crystallized after 7 days of storage at 75%RH/40oC. 
On another hand, no re-crystallization were observed in all SAS co-precipitates after 
storage more than 6 months under same conditions, which indicate SAS co-precipitates 
are more physically stable than COM IDMC-PVPs. The measured Tg values as a 
function of mixture composition were comparable to the ideal Gordon-Taylor equation 
for COM and SAS co-precipitates, which suggested ideal mixing between IDMC and 
PVP. 
 
GVS results show that hydrophobization of PVP phenomena were observed for both 
COM and SAS co-precipitates due to the changes in surfaces energetic and/or 
formation of molecular interaction between IDMC and PVP. FTIR spectra suggested 
the presence of hydrogen bonding formed due to interactions of amide carbonyl groups 
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of PVP with carboxylic acid hydroxyl groups of IDMC in all COM and SAS co-
precipitates. It was observed the IR spectra of all COM and SAS co-precipitates 
showed a distinct loss of the peak height associated with the carboxylic acid 
dimerization of amorphous IDMC over the range of 40-80wt.% of PVP, and the 
development of a new peak related to the formation of IDMC-PVP hydrogen bond. 
Therefore, the amorphous phase present in COM and SAS co-precipitates could have 
been stabilized by the intermolecular hydrogen bond between IDMC and PVP, which 
in turn improved its physical stability against re-crystallization.  
 
IGC studies revealed that different preparation methods used to generate the 
amorphous form have an effect on physical stability in terms of surface structural 
relaxation as well as having different surface energetics. The SAS co-precipitate 
showed lower surface energetic in terms of dispersive and polar component as 
compared to COM sample. Moreover, the overall surface structural relaxation of SAS 
IDMC60-PVP40 co-precipitate was slower than COM IDMC60-PVP40, which 
indicates that the SAS co-precipitate was physically more stable than COM sample. 
Raman mapping results showed the presence of crystalline γ-IDMC phase in COM 
IDMC60-PVP40, which may has acted as the precursor for the re-crystallization of 
COM sample. The Raman spatial distribution mapping suggested that co-linearity in 
composition between PVP and amorphous IDMC in SAS sample, which resulted in the 
reconstruction of single component spectrum that are resemblance to Raman peaks of 
PVP and amorphous IDMC pure component references. By developing greater 
understanding of how the exposure and orientation of molecular groups at individual 
surfaces through modelling and experimental measurements, it can provide some 
predictions of how surface properties can change during subsequent processing.  
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The compositions of both COM IDMC-PVPs and SAS co-precipitates were close to 
the respective feed compositions, which indicate that both processes can be well 
controlled. GC analysis shows that residual solvents content in all the SAS processed 
samples were way below the acceptable maximum limit based on the International 
Conference of Harmonization (ICH) guidelines.  
 
Finally, this work has demonstrated the potential of using a suitable “amorphous 
inducing and stabilizing” agent as a co-precipitant for a poorly water-soluble drug such 
as IDMC to improve the bioavailability using SAS process. The co-precipitant used in 
this work such as PVP to generate amorphous IDMC-PVP co-precipitates using co-
milling and SAS process showed improved physical stability (through hydrogen 
bonding formation between IDMC and PVP) as compared to amorphous IDMC. 
Furthermore, this study could provide a practical reference in helping to evaluate other 
co-precipitants. The amorphous forms of SAS IDMC-PVP co-precipitates have 
increased the dissolution efficiency of IDMC at 5 minutes (DE5%) to about 9-times as 
compared to its crystalline form The use of KWW equation in IGC analysis may has 
provided some useful insights on the amorphous surface structural relaxation prepared 
using COM and SAS processes, which could be related to a faster re-crystallization at 
the surface due to higher surface molecular mobility as compared to the bulk. It could 
also provide some practical insights into the physical stability of pharmaceutical drug-
polymer formulations. 
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6. Future Recommendation Work 
Most of the research work presented in this thesis was related to the effect of polymer 
to drug ratios on the crystallinity or amorphous character of crystalline IDMC for 
dissolution enhancement as well as modifying its physicochemical properties using co-
milling and SAS co-precipitation process. This work has demonstrated the potential of 
using a suitable “amorphous inducing and stabilizing” agent as a co-precipitant for a 
poorly water-soluble drug such as IDMC to improve the bioavailability using SAS 
process. Our results revealed that it is technically feasible to generate X-ray amorphous 
IDMC-PVP with minimum of 40wt.% PVP using co-milling and SAS co-precipitation. 
Improvements can be made by investigating other processing conditions and 
experimental parameters. Below are some of the recommendations for future research 
work. 
 
I. To further understand the amorphous nature/phase separation kinetics 
of amorphous COM and SAS co-precipitates powder 
(IDMC:PVP=60:40), thermal analysis (DSC) could be conducted to 
determine the Tg of SAS amorphous molecular dispersions stored under 
accelerated storage condition (75%RH and 40oC) and monitored 
throughout the studies. The measurement of the drug phase separation 
from the solid dispersion could provide a reliable estimate for the 
kinetics of physical instability. The kinetics of drug phase separation 
could be determined by monitoring the changes in Tg of drug-polymer 
miscible phase. The time-dependent changes Tg values could be used to 
calculate the fraction of the drug phase separated using 1st order rate 
equation such as Kolmogorov-Johnson-Mehl-Avrami (KJMA), 
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II. To study the effect of different molecular weight of PVP on the 
crystallinity or amorphous character of crystalline IDMC for dissolution 
enhancement as well as modifying its physicochemical properties using 
co-milling and SAS co-precipitation process, 
 
III. Another commonly particle/powder formation process such spray-
drying could be employed to co-spray drying IDMC with PVP. The 
effect of polymer to drug ratios on the crystallinity or amorphous 
character of crystalline IDMC for dissolution enhancement as well as 
modifying its physicochemical properties using co-spray drying process 
could be studied and compared to co-milling and SAS co-precipitation 
process in this study, 
 
IV. To evaluate other co-precipitants to co-precipitate with IDMC, such as 
Eudragit, PEG, PVP-VA and other water-soluble polymers using SAS 
process to generate solid dispersion, 
 
V. To evaluate other actives (poorly water-soluble APIs) to co-precipitate 
with PVP using SAS process to generate solid dispersion and/or 
 
VI. To study the effect of SAS co-precipitation processing conditions such 
as pressure, temperature and/or Sc-CO2 flow-rate on SAS co-
precipitates physicochemical properties. 
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